gene	突变类型	突变频率	相关通路	PMID	文献类型	IF	年份	引用量	备注	Drug_anno(敏感增加或.)	Drug_anno(毒性增加或敏感降低或耐药提高)
TERT	promotor mut	60.00%	Telomere maintenance	27838634	Review	5.03	2017	8		Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	HBV int、mut	60.00%		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	promotor mut	60.00%		27262756	Review	7.43	2016	12		Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	promotor mut	44.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	promotor mut	26.00%		.	.	.	.	.	来源于cosmic	Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	promotor mut	58.00%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	promotor mut	3.00%		28297679		8.4	2017	8	仅在第一阶段出现	Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	promotor mut	43.00%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	HBV int	22.00%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	amp	6.70%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	promotor mut	10.50%		28843658	research	7.43	2017	0	85%的原发瘤和转移瘤中存在TP53\CTNNB1\TERT突变	Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	promotor mut	15.20%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	promotor mut	55.8%（432/774）		26099984	Review	4.91	2015	86		Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	amp	10/547 (1.6)§		26099984	Review	4.91	2015	86		Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	promoter mut	54-60%		26099527	Review	7.67	2015	77		Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
TERT	amp	5-6%		26099527	Review	7.67	2015	77		Eribulin:PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	None
ARID1A	mut	12.00%	DNA damage checkpoint and repair	27838634	Review	5.03	2017	8		None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	25.9%（7/27）；10%(12/120)	.	22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	11.7%(35/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	13.00%	Chromatin remodelling	27262756	Review	7.43	2016	12		None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	7.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A		7.00%		.	.	.	.	.	来源于cosmic	None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	12.80%	chromatin remodeling	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A		13.00%		26405193	research	8.39	2015	19		None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A		8.80%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	17.40%	Epigenetic modifiers	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	16.00%	chromatin remodeling	28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	8-17%	chromatin remodeling	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	19.00%		24185509	research	24.17	2013	164	32 iCC，9 gall-bladder carcinomas	None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	54/928 (5.8)*	Chromatin remodeling	26099984	Review	4.91	2015	86		None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	10%（12/120）		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
ARID1A	mut	4-17%	Epigenetic modifiers	26099527	Review	7.67	2015	77		None	Trastuzumab:PMID: 27172896||Trastuzumab:PMID: 27172896
TP53	mut	32.00%	genomic instability	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53	mut	8.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53		16.00%		26405193	research	8.39	2015	19		AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53		29.10%	HCC	29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53	mut	31.00%	p53-Rb pathway	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53	mut	24.35%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53	mut	23.00%		28843658	research	7.43	2017	0	85%的原发瘤和转移瘤中存在TP53\CTNNB1\TERT突变	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53	mut	27%（251/928)	p53/cell cycle control	26099984	Review	4.91	2015	86		AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53	del	3.7%（20/547)	TP53/cell-cycle control	26099984	Review	4.91	2015	86		AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53	mut	31.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中.该研究显示肝癌患者CLA4\PD1\PDL1药物获益可能较高	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53		27.00%		.	.	.	.	.	来源于cosmic	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53	mut	30.00%	cell cycle control	27262756	Review	7.43	2016	12		AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53	mut	26.3%(79/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53	mut	35-50%	DNA damage checkpoint and repair	27838634	Review	5.03	2017	8		AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
TP53	mut	12-48%	P53-cell cycle pathway	26099527	Review	7.67	2015	77		AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Pramlintide:PMID: 25409149||AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html;Decitabine:PMID: 27959731;Doxorubicin:PMID: 27397505;Gemcitabine:PMID: 27397505;Mitomycin C:PMID: 27397505;MK-1775:NCT01357161,ASCO2015 (abstr 2507);Pramlintide:PMID: 25409149||HSP90 inhibitors:PMID: 26009011||HSP90 inhibitors:PMID: 26009011||Nutlin-3a:PMID:  27813088	Abemaciclib:PMID: 27217383;Cisplatin:PMID: 27646943||Nutlin-3a:PMID:  27813088
ARID2	mut	7.00%	DNA damage checkpoint and repair	27838634	Review	5.03	2017	8		None	None
ARID2	mut	11.1%（3/27）；		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
ARID2	mut	8.7%(26/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
ARID2	mut	7.00%	Chromatin remodelling	27262756	Review	7.43	2016	12		None	None
ARID2	mut	5.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
ARID2		5.00%		.	.	.	.	.	来源于cosmic	None	None
ARID2	mut	6.80%	chromatin remodeling	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
ARID2		8.20%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	None	None
ARID2	mut	3.40%	Epigenetic modifiers	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
ARID2	mut	13.00%	chromatin remodeling	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
ARID2		7.40%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	None	None
ARID2	mut	62/928 (6.7)	Chromatin remodeling	26099984	Review	4.91	2015	86		None	None
ARID2	mut	5.8%(7/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
ARID2	mut	3-18%	Epigenetic modifiers	26099527	Review	7.67	2015	77		None	None
CDKN2A	mut	6-30%		27838634	Review	5.03	2017	8		Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A	(STV)CNV	11.3%(34/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A	mut	8.00%	cell cycle control	27262756	Review	7.43	2016	12		Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A	mut	2.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A	del	13.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A		6.00%		.	.	.	.	.	来源于cosmic	Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A	mut,homo del	8.50%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A		3-4%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A	CNV,epigenetic silencing	47.00%		28297679		8.4	2017	8	仅在第一阶段出现	Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A	del，mut	7.00%	p53-Rb pathway	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A	mut	13/928 (1.4)	p53/cell cycle control	26099984	Review	4.91	2015	86		Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A	del	4.7%（26/547）	TP53/cell-cycle control	26099984	Review	4.91	2015	86		Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
CDKN2A	homo del	2-12%	P53-cell cycle pathway	26099527	Review	7.67	2015	77		Ilorasertib:NCT02478320||Ilorasertib:NCT02478320||Palbociclib:PMID:  29487225	None
RB1		0-14%		27838634	Review	5.03	2017	8		Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1	SNP、Indel、SV	5.7%（17/300）		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1	mut/del	8.00%	cell cycle control	27262756	Review	7.43	2016	12		Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1	mut	4.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1	del	19.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1		3.00%		.	.	.	.	.	来源于cosmic	Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1	mut,homo del	3.80%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1		4.00%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1	mut	2.80%	Cell cycle	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1	mut	5.00%	p53-Rb pathway	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1	mut	3%（28/928）	p53/cell cycle control	26099984	Review	4.91	2015	86		Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1	del	3.7%（20/547）	TP53/cell-cycle control	26099984	Review	4.91	2015	86		Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
RB1	homo del	3-8%	P53-cell cycle pathway	26099527	Review	7.67	2015	77		Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431||Palbociclib:PMID: 23708653	None
AXIN1	mut	9-13%	Wnt signaling	27838634	Review	5.03	2017	8		None	None
AXIN1	mut	4.7%(14/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
AXIN1	mut	11.00%	WNT Signalling	27262756	Review	7.43	2016	12		None	None
AXIN1	mut	8.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
AXIN1		18.00%		.	.	.	.	.	来源于cosmic	None	None
AXIN1	mut,homo del	11.10%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
AXIN1		7.50%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	None	None
AXIN1	mut	10.00%	β-catenin	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
AXIN1	mut	45/928 (4.8)*	Wnt/β-catenin signalling	26099984	Review	4.91	2015	86		None	None
AXIN1	del	16/547 (2.9)	Wnt/β-catenin signalling	26099984	Review	4.91	2015	86		None	None
AXIN1	mut	5-15%	Wnt/β-catenin	26099527	Review	7.67	2015	77		None	None
CTNNB1	mut	20-40%	Wnt signaling	27838634	Review	5.03	2017	8		None	None
CTNNB1	mut	24%(72/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
CTNNB1	mut	30.00%	WNT Signalling	27262756	Review	7.43	2016	12		None	None
CTNNB1	mut	27.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
CTNNB1		19.00%		.	.	.	.	.	来源于cosmic	None	None
CTNNB1	mut	37.40%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
CTNNB1		28.60%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	None	None
CTNNB1	mut	1.30%	WNT signalling	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
CTNNB1	mut	~30%	β-catenin	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
CTNNB1	mut	26.3%（244/928）	Wnt/β-catenin signalling	26099984	Review	4.91	2015	86		None	None
CTNNB1	mut	11-37%	Wnt/β-catenin	26099527	Review	7.67	2015	77		None	None
PIK3CA	mut	2.00%	PI3K/MTOR signalling	27262756	Review	7.43	2016	12		BKM120:PMID: 20453058, 23714559;Everolimus:PMID: 20453058, 23714559;GDC-0941:PMID: 20453058, 23714559;MK-2206:PMID: 20453058, 23714559;PP24237:PMID: 20453058, 23714559;Temsirolimus:PMID: 20453058, 23714559||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BRAF inhibitors:PMC3936420;Dabrafenib:PMID: 24265155;Vemurafenib:PMID: 24265155||Cetuximab:PMID: 19223544, 20619739||EGFR TKIs:PMID: 16906227
PIK3CA		0-35%		27838634	Review	5.03	2017	8		BKM120:PMID: 20453058, 23714559;Everolimus:PMID: 20453058, 23714559;GDC-0941:PMID: 20453058, 23714559;MK-2206:PMID: 20453058, 23714559;PP24237:PMID: 20453058, 23714559;Temsirolimus:PMID: 20453058, 23714559||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BRAF inhibitors:PMC3936420;Dabrafenib:PMID: 24265155;Vemurafenib:PMID: 24265155||Cetuximab:PMID: 19223544, 20619739||EGFR TKIs:PMID: 16906227
PIK3CA	mut	4.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	BKM120:PMID: 20453058, 23714559;Everolimus:PMID: 20453058, 23714559;GDC-0941:PMID: 20453058, 23714559;MK-2206:PMID: 20453058, 23714559;PP24237:PMID: 20453058, 23714559;Temsirolimus:PMID: 20453058, 23714559||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BRAF inhibitors:PMC3936420;Dabrafenib:PMID: 24265155;Vemurafenib:PMID: 24265155||Cetuximab:PMID: 19223544, 20619739||EGFR TKIs:PMID: 16906227
PIK3CA		3.00%		.	.	.	.	.	来源于cosmic	BKM120:PMID: 20453058, 23714559;Everolimus:PMID: 20453058, 23714559;GDC-0941:PMID: 20453058, 23714559;MK-2206:PMID: 20453058, 23714559;PP24237:PMID: 20453058, 23714559;Temsirolimus:PMID: 20453058, 23714559||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BRAF inhibitors:PMC3936420;Dabrafenib:PMID: 24265155;Vemurafenib:PMID: 24265155||Cetuximab:PMID: 19223544, 20619739||EGFR TKIs:PMID: 16906227
PIK3CA	mut	1.70%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	BKM120:PMID: 20453058, 23714559;Everolimus:PMID: 20453058, 23714559;GDC-0941:PMID: 20453058, 23714559;MK-2206:PMID: 20453058, 23714559;PP24237:PMID: 20453058, 23714559;Temsirolimus:PMID: 20453058, 23714559||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BRAF inhibitors:PMC3936420;Dabrafenib:PMID: 24265155;Vemurafenib:PMID: 24265155||Cetuximab:PMID: 19223544, 20619739||EGFR TKIs:PMID: 16906227
PIK3CA		2.00%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	BKM120:PMID: 20453058, 23714559;Everolimus:PMID: 20453058, 23714559;GDC-0941:PMID: 20453058, 23714559;MK-2206:PMID: 20453058, 23714559;PP24237:PMID: 20453058, 23714559;Temsirolimus:PMID: 20453058, 23714559||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BRAF inhibitors:PMC3936420;Dabrafenib:PMID: 24265155;Vemurafenib:PMID: 24265155||Cetuximab:PMID: 19223544, 20619739||EGFR TKIs:PMID: 16906227
PIK3CA	mut	4.50%	RAS/RAF kinase	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	BKM120:PMID: 20453058, 23714559;Everolimus:PMID: 20453058, 23714559;GDC-0941:PMID: 20453058, 23714559;MK-2206:PMID: 20453058, 23714559;PP24237:PMID: 20453058, 23714559;Temsirolimus:PMID: 20453058, 23714559||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BRAF inhibitors:PMC3936420;Dabrafenib:PMID: 24265155;Vemurafenib:PMID: 24265155||Cetuximab:PMID: 19223544, 20619739||EGFR TKIs:PMID: 16906227
PIK3CA	mut	5.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	BKM120:PMID: 20453058, 23714559;Everolimus:PMID: 20453058, 23714559;GDC-0941:PMID: 20453058, 23714559;MK-2206:PMID: 20453058, 23714559;PP24237:PMID: 20453058, 23714559;Temsirolimus:PMID: 20453058, 23714559||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BRAF inhibitors:PMC3936420;Dabrafenib:PMID: 24265155;Vemurafenib:PMID: 24265155||Cetuximab:PMID: 19223544, 20619739||EGFR TKIs:PMID: 16906227
PIK3CA	mut	14/928 (1.5)	Ras/PI3K/mTOR pathway	26099984	Review	4.91	2015	86		BKM120:PMID: 20453058, 23714559;Everolimus:PMID: 20453058, 23714559;GDC-0941:PMID: 20453058, 23714559;MK-2206:PMID: 20453058, 23714559;PP24237:PMID: 20453058, 23714559;Temsirolimus:PMID: 20453058, 23714559||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BRAF inhibitors:PMC3936420;Dabrafenib:PMID: 24265155;Vemurafenib:PMID: 24265155||Cetuximab:PMID: 19223544, 20619739||EGFR TKIs:PMID: 16906227
PIK3CA	mut	0-2%	Akt/mtor	26099527	Review	7.67	2015	77		BKM120:PMID: 20453058, 23714559;Everolimus:PMID: 20453058, 23714559;GDC-0941:PMID: 20453058, 23714559;MK-2206:PMID: 20453058, 23714559;PP24237:PMID: 20453058, 23714559;Temsirolimus:PMID: 20453058, 23714559||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BRAF inhibitors:PMC3936420;Dabrafenib:PMID: 24265155;Vemurafenib:PMID: 24265155||Cetuximab:PMID: 19223544, 20619739||EGFR TKIs:PMID: 16906227
PTEN		3.00%		27838634	Review	5.03	2017	8		Everolimus:PMID: 22932669, 23714559;MK-2206:PMID: 22932669, 23714559;Temsirolimus:PMID: 22932669, 23714559||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BYL719:PMID: 25409150;Cetuximab:Caris molecular intelligence;Panitumumab:Caris molecular intelligence||Cetuximab:PMID: 21163703||Cetuximab:PMID: 21163703
PTEN	mut	4.3%(13/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	Everolimus:PMID: 22932669, 23714559;MK-2206:PMID: 22932669, 23714559;Temsirolimus:PMID: 22932669, 23714559||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BYL719:PMID: 25409150;Cetuximab:Caris molecular intelligence;Panitumumab:Caris molecular intelligence||Cetuximab:PMID: 21163703||Cetuximab:PMID: 21163703
PTEN	del	7.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	Everolimus:PMID: 22932669, 23714559;MK-2206:PMID: 22932669, 23714559;Temsirolimus:PMID: 22932669, 23714559||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BYL719:PMID: 25409150;Cetuximab:Caris molecular intelligence;Panitumumab:Caris molecular intelligence||Cetuximab:PMID: 21163703||Cetuximab:PMID: 21163703
PTEN	mut,homo del	3.40%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Everolimus:PMID: 22932669, 23714559;MK-2206:PMID: 22932669, 23714559;Temsirolimus:PMID: 22932669, 23714559||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BYL719:PMID: 25409150;Cetuximab:Caris molecular intelligence;Panitumumab:Caris molecular intelligence||Cetuximab:PMID: 21163703||Cetuximab:PMID: 21163703
PTEN		2.00%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	Everolimus:PMID: 22932669, 23714559;MK-2206:PMID: 22932669, 23714559;Temsirolimus:PMID: 22932669, 23714559||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BYL719:PMID: 25409150;Cetuximab:Caris molecular intelligence;Panitumumab:Caris molecular intelligence||Cetuximab:PMID: 21163703||Cetuximab:PMID: 21163703
PTEN	mut	2.60%	RAS/RAF kinase	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Everolimus:PMID: 22932669, 23714559;MK-2206:PMID: 22932669, 23714559;Temsirolimus:PMID: 22932669, 23714559||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BYL719:PMID: 25409150;Cetuximab:Caris molecular intelligence;Panitumumab:Caris molecular intelligence||Cetuximab:PMID: 21163703||Cetuximab:PMID: 21163703
PTEN	mut	3.00%		28297679		8.4	2017	8	仅在第一阶段出现	Everolimus:PMID: 22932669, 23714559;MK-2206:PMID: 22932669, 23714559;Temsirolimus:PMID: 22932669, 23714559||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BYL719:PMID: 25409150;Cetuximab:Caris molecular intelligence;Panitumumab:Caris molecular intelligence||Cetuximab:PMID: 21163703||Cetuximab:PMID: 21163703
PTEN	del，mut	3.00%	PIK3-mTOR	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Everolimus:PMID: 22932669, 23714559;MK-2206:PMID: 22932669, 23714559;Temsirolimus:PMID: 22932669, 23714559||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BYL719:PMID: 25409150;Cetuximab:Caris molecular intelligence;Panitumumab:Caris molecular intelligence||Cetuximab:PMID: 21163703||Cetuximab:PMID: 21163703
PTEN	mut	9/928 (1)	Ras/PI3K/mTOR pathway	26099984	Review	4.91	2015	86		Everolimus:PMID: 22932669, 23714559;MK-2206:PMID: 22932669, 23714559;Temsirolimus:PMID: 22932669, 23714559||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BYL719:PMID: 25409150;Cetuximab:Caris molecular intelligence;Panitumumab:Caris molecular intelligence||Cetuximab:PMID: 21163703||Cetuximab:PMID: 21163703
PTEN	homo del	1-3%	Akt/mtor	26099527	Review	7.67	2015	77		Everolimus:PMID: 22932669, 23714559;MK-2206:PMID: 22932669, 23714559;Temsirolimus:PMID: 22932669, 23714559||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 23582881;Sirolimus:ASCO 2013 (abstr 2532)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708	BYL719:PMID: 25409150;Cetuximab:Caris molecular intelligence;Panitumumab:Caris molecular intelligence||Cetuximab:PMID: 21163703||Cetuximab:PMID: 21163703
ALB	mut	5.00%	unclear	27838634	Review	5.03	2017	8		None	None
ALB	mut	3.3%(4/120)		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
ALB	mut	13%(39/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
ALB	mut	13.00%	hepatic differentiation	27262756	Review	7.43	2016	12		None	None
ALB	mut	13.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
ALB	mut	12.80%	hepatic differentiation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
ALB		10.20%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	None	None
ALB	mut	8.00%		28297679		8.4	2017	8	仅在第一阶段出现	None	None
ALB	mut	3.3%(4/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
ATM	mut	7%-19%	DNA damage checkpoint and repair	27838634	Review	5.03	2017	8		AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html||CHK1/2 inhibitor:PMID: 24934408;Irinotecan:PMID: 24934408||Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431;Olaparib:ENA 2014 (abstr 8LBA), 26510020;Temozolomide:PMID: 23960094	None
ATM	mut	5%（6/120）		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html||CHK1/2 inhibitor:PMID: 24934408;Irinotecan:PMID: 24934408||Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431;Olaparib:ENA 2014 (abstr 8LBA), 26510020;Temozolomide:PMID: 23960094	None
ATM	mut	6.00%	cell cycle control	27262756	Review	7.43	2016	12		AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html||CHK1/2 inhibitor:PMID: 24934408;Irinotecan:PMID: 24934408||Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431;Olaparib:ENA 2014 (abstr 8LBA), 26510020;Temozolomide:PMID: 23960094	None
ATM		3.00%		.	.	.	.	.	来源于cosmic	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html||CHK1/2 inhibitor:PMID: 24934408;Irinotecan:PMID: 24934408||Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431;Olaparib:ENA 2014 (abstr 8LBA), 26510020;Temozolomide:PMID: 23960094	None
ATM	mut	5.50%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html||CHK1/2 inhibitor:PMID: 24934408;Irinotecan:PMID: 24934408||Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431;Olaparib:ENA 2014 (abstr 8LBA), 26510020;Temozolomide:PMID: 23960094	None
ATM	mut	3.00%		28297679		8.4	2017	8	仅在第一阶段出现	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html||CHK1/2 inhibitor:PMID: 24934408;Irinotecan:PMID: 24934408||Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431;Olaparib:ENA 2014 (abstr 8LBA), 26510020;Temozolomide:PMID: 23960094	None
ATM	mut	30/928 (3.2)	p53/cell cycle control	26099984	Review	4.91	2015	86		AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html||CHK1/2 inhibitor:PMID: 24934408;Irinotecan:PMID: 24934408||Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431;Olaparib:ENA 2014 (abstr 8LBA), 26510020;Temozolomide:PMID: 23960094	None
ATM	mut	5.0%(6/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html||CHK1/2 inhibitor:PMID: 24934408;Irinotecan:PMID: 24934408||Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431;Olaparib:ENA 2014 (abstr 8LBA), 26510020;Temozolomide:PMID: 23960094	None
ATM	mut	2-6%	P53-cell cycle pathway	26099527	Review	7.67	2015	77		AZD6738:NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html||CHK1/2 inhibitor:PMID: 24934408;Irinotecan:PMID: 24934408||Cisplatin:PMID: 26238431||Cisplatin:PMID: 26238431;Olaparib:ENA 2014 (abstr 8LBA), 26510020;Temozolomide:PMID: 23960094	None
CCND1	(STV)CNV	5.3%(16/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Palbociclib:ASCO 2017 (abstr 9056)
CCND1	amp	7.00%	cell cycle control	27262756	Review	7.43	2016	12		None	Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Palbociclib:ASCO 2017 (abstr 9056)
CCND1	amp	6.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Palbociclib:ASCO 2017 (abstr 9056)
CCND1	amp	4.70%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Palbociclib:ASCO 2017 (abstr 9056)
CCND1		1-2%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	None	Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Palbociclib:ASCO 2017 (abstr 9056)
CCND1	amp	13.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	None	Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Palbociclib:ASCO 2017 (abstr 9056)
CCND1	amp	7.00%	p53-Rb pathway，β-catenin	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Palbociclib:ASCO 2017 (abstr 9056)
CCND1	amp	46/636 (7.2)‡	Cell-cycle control	26099984	Review	4.91	2015	86		None	Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Palbociclib:ASCO 2017 (abstr 9056)
CCND1	amp	5-14%	P53-cell cycle pathway	26099527	Review	7.67	2015	77		None	Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Ibrutinib:PMID: 27713153||Palbociclib:ASCO 2017 (abstr 9056)
NFE2L2	mut	5.00%	oxidative stress response	27838634	Review	5.03	2017	8		None	None
NFE2L2	mut	3.3%(10/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
NFE2L2	mut	6.00%	Oxidative stress	27262756	Review	7.43	2016	12		None	None
NFE2L2	mut	3.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
NFE2L2		3.00%		.	.	.	.	.	来源于cosmic	None	None
NFE2L2	mut	6.40%	Oxidative stress	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
NFE2L2	mut	7.00%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
NFE2L2	mut	32/928 (3.4)	Oxidative stress	26099984	Review	4.91	2015	86		None	None
NFE2L2	mut	3-6 %	oxidative stress	26099527	Review	7.67	2015	77		None	None
RPS6KA3	mut	8%-10%	DNA damage checkpoint and repair	27838634	Review	5.03	2017	8		None	None
RPS6KA3	SNP、Indel、SV	6.3%(19/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
RPS6KA3	mut	7.00%	RAS/MAPK signalling	27262756	Review	7.43	2016	12		None	None
RPS6KA3	mut	4.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
RPS6KA3	mut	6.80%	MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
RPS6KA3		4.00%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	None	None
RPS6KA3	mut	5.00%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
RPS6KA3	mut	30/928 (3.2)	Ras/PI3K/mTOR pathway	26099984	Review	4.91	2015	86		None	None
RPS6KA3	mut	2-9%	Ras/raf/mapk	26099527	Review	7.67	2015	77		None	None
BAP1	mut	2.7%(8/300)	chromatin remodeling	27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
BAP1	mut	5.00%	chromatin remodeling	28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
BAP1		11.00%	chromatin remodeling	26405193	research	8.39	2015	19		None	None
BAP1	mut	8.50%	Epigenetic modifiers,chromatin-remodeling	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
BAP1	mut	32.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	None	None
BAP1	mut	25.00%		24185509	research	24.17	2013	164	32 iCC，9 gall-bladder carcinomas	None	None
BAP1		5.90%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	None	None
ACVR2A	mut	3.3%(10/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
ACVR2A	mut	4.00%	TGFβ signalling	27262756	Review	7.43	2016	12		None	None
ACVR2A	mut	3.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
ACVR2A	mut	4.10%	TGF-β	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
ACVR2A	mut	5.00%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
ACVR2A	mut	4.70%	TGFβ pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
APC	mut	1.00%	WNT Signalling	27262756	Review	7.43	2016	12		None	None
APC	mut	1.30%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
APC	mut	7.10%	WNT signalling	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
APC	mut	3.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	None	None
APC	mut	15/928 (1.6)	Wnt/β-catenin signalling	26099984	Review	4.91	2015	86		None	None
APC	mut	1-2%	Wnt/β-catenin	26099527	Review	7.67	2015	77		None	None
FGF19	amp	4.00%	RAS/MAPK signalling	27262756	Review	7.43	2016	12		None	None
FGF19	amp	4.30%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
FGF19	amp	4.70%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
FGF19	amp	7.00%	β-catenin	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
FGF19	amp	36/636 (5.6)‡	FGF signalling	26099984	Review	4.91	2015	86		None	None
FGF19	amp	5-14%	P53-cell cycle pathway	26099527	Review	7.67	2015	77		None	None
FGFR2	mut	0.40%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:ENA 2014 (abstr 381)||FGFR inhibitors:PMID: 23786770, 25035393||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597	Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597
FGFR2	fusion	23.00%		26405193	research	8.39	2015	19		FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:ENA 2014 (abstr 381)||FGFR inhibitors:PMID: 23786770, 25035393||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597	Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597
FGFR2	mut	2.80%		28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:ENA 2014 (abstr 381)||FGFR inhibitors:PMID: 23786770, 25035393||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597	Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597
FGFR2	mut，fusion	21.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:ENA 2014 (abstr 381)||FGFR inhibitors:PMID: 23786770, 25035393||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597	Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597
FGFR2	mut	1.80%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:ENA 2014 (abstr 381)||FGFR inhibitors:PMID: 23786770, 25035393||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597	Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597
FGFR2		13.00%		24185509	research	24.17	2013	164	32 iCC，9 gall-bladder carcinomas	FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 18552176, 22238366, 23002168||FGFR inhibitors:PMID: 23786770, 25035393||FGFR inhibitors:ENA 2014 (abstr 381)||FGFR inhibitors:PMID: 23786770, 25035393||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597||Ponatinib:PMID: 23908597	Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597||Dovitinib:PMID: 23908597
KEAP1	mut	4.00%	Oxidative stress	27262756	Review	7.43	2016	12		None	None
KEAP1	mut	5.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
KEAP1		2.00%		.	.	.	.	.	来源于cosmic	None	None
KEAP1	mut	3.80%	Oxidative stress	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
KEAP1	mut	3.1%（29/928）	Oxidative stress	26099984	Review	4.91	2015	86		None	None
KEAP1	mut	2-8%	oxidative stress	26099527	Review	7.67	2015	77		None	None
MLL3	mut	4.00%	transcription	27838634	Review	5.03	2017	8		None	None
MLL3	mut	11.1%（3/27）；		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
MLL3	mut	2.10%	epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
MLL3	mut	3.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	None	None
MLL3	mut	4.2%(5/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
MLL3	mut	3-6%	Epigenetic modifiers	26099527	Review	7.67	2015	77		None	None
NTRK3	mut	3.00%	RAS/MAPK signalling	27262756	Review	7.43	2016	12		Midostaurin:PMID: 21148487, 23131561	Entrectinib:PMID: 26884591;Type I TKIs:PMID: 28625641
NTRK3	mut	3.00%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Midostaurin:PMID: 21148487, 23131561	Entrectinib:PMID: 26884591;Type I TKIs:PMID: 28625641
NTRK3	mut	3.00%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Midostaurin:PMID: 21148487, 23131561	Entrectinib:PMID: 26884591;Type I TKIs:PMID: 28625641
NTRK3	mut	3.00%	RAS/MAPK signalling	27262756	Review	7.43	2016	12		Midostaurin:PMID: 21148487, 23131561	Entrectinib:PMID: 26884591;Type I TKIs:PMID: 28625641
NTRK3	mut	3.00%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Midostaurin:PMID: 21148487, 23131561	Entrectinib:PMID: 26884591;Type I TKIs:PMID: 28625641
NTRK3	mut	3.00%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Midostaurin:PMID: 21148487, 23131561	Entrectinib:PMID: 26884591;Type I TKIs:PMID: 28625641
TSC2	mut	7.00%	PIK3-mTOR	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Everolimus or Temsirolimus:PMID: 22923433;Everolimus or Temsirolimus:FDA	None
TSC2	mut	3-8%	Ras/raf/mapk	26099527	Review	7.67	2015	77		Everolimus or Temsirolimus:PMID: 22923433;Everolimus or Temsirolimus:FDA	None
TSC2		2-3%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	Everolimus or Temsirolimus:PMID: 22923433;Everolimus or Temsirolimus:FDA	None
TSC2	mut	5.10%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Everolimus or Temsirolimus:PMID: 22923433;Everolimus or Temsirolimus:FDA	None
TSC2		3.00%		.	.	.	.	.	来源于cosmic	Everolimus or Temsirolimus:PMID: 22923433;Everolimus or Temsirolimus:FDA	None
TSC2	mut	5.00%	PI3K/MTOR signalling	27262756	Review	7.43	2016	12		Everolimus or Temsirolimus:PMID: 22923433;Everolimus or Temsirolimus:FDA	None
APOB	mut	9.3%(28/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
APOB	mut	9.00%	hepatic differentiation	27262756	Review	7.43	2016	12		None	None
APOB	mut	10.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
APOB	mut	9.40%	hepatic differentiation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
APOB	mut	9.80%		29573058	Review	4.14	2018	0	整合1340例样本分析；642来自日本，451来自TCGA，247来自芬兰	None	None
EGFR	mut,amp	1.30%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Erlotinib:NCCN;Erlotinib:FDA;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728;Osimertinib:NCT02465060||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Erlotinib:NCCN;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:PMID: 27553514;Afatinib + Cetuximab:PMID: 25074459;Afatinib + Nimotuzumab:PMID: 26667485;AZD9291:PMID: 25939061;AZD9291:PMID: 26473643;EGFR inhibitor 3rd gens:ASCO 2014 (abstr 8009),ENA 2014 (abstr 10LBA),ENA 2014 (abstr 9LBA),ASCO 2015 (abstr 8001);Erlotinib:PMID: 21430269;Erlotinib:PMID: 24781527;Gefitinib:PMID: 18509184;Gefitinib:PMID: 20686428;Gefitinib:PMID: 20871262;Gefitinib:PMID: 21030498;Gefitinib:PMID: 22215752;Gefitinib:PMID: 22815900;Gefitinib:PMID: 23180674;Gefitinib:PMID: 23407566;Gefitinib:PMID: 23886554;HM61713:NCT02322281;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728;Osimertinib:FDA;Rociletinib:NCT02322281;Tyrosine kinase inhibitor - NS:PMID: 22773810;Tyrosine kinase inhibitor - NS:PMID: 25939061;Tyrosine kinase inhibitor - NS:PMID: 23542356;Tyrosine kinase inhibitor - NS:PMID: 24035188||Afatinib:FDA;Erlotinib:FDA;Gefitinib:FDA;Osimertinib:NCT02465060||Afatinib:PMID: 22753918, 25589191;Afatinib:ESMO 2012 (abstr 1289);Cetuximab:ESMO 2012 (abstr 1289);Erlotinib:PMID: 22190593||AZD9291:PMID: 25939061||Cetuximab:PMID: 23578570||Cetuximab:FDA||Cetuximab + Sirolimus:PMID: 24934779||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740||Erlotinib:PMID: 17177598||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740, 23328547||Erlotinib:NCCN||Erlotinib:PMID: 27102076;Erlotinib:PMID: 27102076||Gefitinib:PMID: 24950987||Lapatinib:PMID: 22885469||novel EGFR mAb inhibitors:PMID: 25962717;Panitumumab:PMID: 22270724||Osimertinib:PMID: 26515464||Rindopepimut:NCT01480479	Afatinib:.||Afatinib:.||Afatinib:NCCN;EGFR inhibitor 1st gens:PMID: 19680293;EGFR inhibitor 2nd gens:PMID: 22452896;Erlotinib:NCCN;Erlotinib:.;Gefitinib:.;Lapatinib:.||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827;Cetuximab:PMID: 25623215;Panitumumab:PMID: 26059438||Cetuximab:PMID: 25623215||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 25623215||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||EGFR inhibitor 3rd gens:PMID: 25939061||EGFR inhibitor 1st gens:PMID: 19680293;Erlotinib:PMID: 19680293||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:PMID: 26773740||Erlotinib:ASCO2015(abstre19028);Gefitinib:PMID: 21274259, 22261807||Gefitinib:PMID: 21274259||Gefitinib:PMID: 21274259||Osimertinib:ASCO 2017 (abstr 2572)||Osimertinib:ASCO 2017 (abstr 2572)||Panitumumab:FDA guidelines||Rociletinib:PMID: 27283993
EGFR		3.00%		26405193	research	8.39	2015	19		Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Erlotinib:NCCN;Erlotinib:FDA;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728;Osimertinib:NCT02465060||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Erlotinib:NCCN;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:PMID: 27553514;Afatinib + Cetuximab:PMID: 25074459;Afatinib + Nimotuzumab:PMID: 26667485;AZD9291:PMID: 25939061;AZD9291:PMID: 26473643;EGFR inhibitor 3rd gens:ASCO 2014 (abstr 8009),ENA 2014 (abstr 10LBA),ENA 2014 (abstr 9LBA),ASCO 2015 (abstr 8001);Erlotinib:PMID: 21430269;Erlotinib:PMID: 24781527;Gefitinib:PMID: 18509184;Gefitinib:PMID: 20686428;Gefitinib:PMID: 20871262;Gefitinib:PMID: 21030498;Gefitinib:PMID: 22215752;Gefitinib:PMID: 22815900;Gefitinib:PMID: 23180674;Gefitinib:PMID: 23407566;Gefitinib:PMID: 23886554;HM61713:NCT02322281;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728;Osimertinib:FDA;Rociletinib:NCT02322281;Tyrosine kinase inhibitor - NS:PMID: 22773810;Tyrosine kinase inhibitor - NS:PMID: 25939061;Tyrosine kinase inhibitor - NS:PMID: 23542356;Tyrosine kinase inhibitor - NS:PMID: 24035188||Afatinib:FDA;Erlotinib:FDA;Gefitinib:FDA;Osimertinib:NCT02465060||Afatinib:PMID: 22753918, 25589191;Afatinib:ESMO 2012 (abstr 1289);Cetuximab:ESMO 2012 (abstr 1289);Erlotinib:PMID: 22190593||AZD9291:PMID: 25939061||Cetuximab:PMID: 23578570||Cetuximab:FDA||Cetuximab + Sirolimus:PMID: 24934779||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740||Erlotinib:PMID: 17177598||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740, 23328547||Erlotinib:NCCN||Erlotinib:PMID: 27102076;Erlotinib:PMID: 27102076||Gefitinib:PMID: 24950987||Lapatinib:PMID: 22885469||novel EGFR mAb inhibitors:PMID: 25962717;Panitumumab:PMID: 22270724||Osimertinib:PMID: 26515464||Rindopepimut:NCT01480479	Afatinib:.||Afatinib:.||Afatinib:NCCN;EGFR inhibitor 1st gens:PMID: 19680293;EGFR inhibitor 2nd gens:PMID: 22452896;Erlotinib:NCCN;Erlotinib:.;Gefitinib:.;Lapatinib:.||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827;Cetuximab:PMID: 25623215;Panitumumab:PMID: 26059438||Cetuximab:PMID: 25623215||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 25623215||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||EGFR inhibitor 3rd gens:PMID: 25939061||EGFR inhibitor 1st gens:PMID: 19680293;Erlotinib:PMID: 19680293||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:PMID: 26773740||Erlotinib:ASCO2015(abstre19028);Gefitinib:PMID: 21274259, 22261807||Gefitinib:PMID: 21274259||Gefitinib:PMID: 21274259||Osimertinib:ASCO 2017 (abstr 2572)||Osimertinib:ASCO 2017 (abstr 2572)||Panitumumab:FDA guidelines||Rociletinib:PMID: 27283993
EGFR	amp	3.10%		28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Erlotinib:NCCN;Erlotinib:FDA;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728;Osimertinib:NCT02465060||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Erlotinib:NCCN;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:PMID: 27553514;Afatinib + Cetuximab:PMID: 25074459;Afatinib + Nimotuzumab:PMID: 26667485;AZD9291:PMID: 25939061;AZD9291:PMID: 26473643;EGFR inhibitor 3rd gens:ASCO 2014 (abstr 8009),ENA 2014 (abstr 10LBA),ENA 2014 (abstr 9LBA),ASCO 2015 (abstr 8001);Erlotinib:PMID: 21430269;Erlotinib:PMID: 24781527;Gefitinib:PMID: 18509184;Gefitinib:PMID: 20686428;Gefitinib:PMID: 20871262;Gefitinib:PMID: 21030498;Gefitinib:PMID: 22215752;Gefitinib:PMID: 22815900;Gefitinib:PMID: 23180674;Gefitinib:PMID: 23407566;Gefitinib:PMID: 23886554;HM61713:NCT02322281;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728;Osimertinib:FDA;Rociletinib:NCT02322281;Tyrosine kinase inhibitor - NS:PMID: 22773810;Tyrosine kinase inhibitor - NS:PMID: 25939061;Tyrosine kinase inhibitor - NS:PMID: 23542356;Tyrosine kinase inhibitor - NS:PMID: 24035188||Afatinib:FDA;Erlotinib:FDA;Gefitinib:FDA;Osimertinib:NCT02465060||Afatinib:PMID: 22753918, 25589191;Afatinib:ESMO 2012 (abstr 1289);Cetuximab:ESMO 2012 (abstr 1289);Erlotinib:PMID: 22190593||AZD9291:PMID: 25939061||Cetuximab:PMID: 23578570||Cetuximab:FDA||Cetuximab + Sirolimus:PMID: 24934779||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740||Erlotinib:PMID: 17177598||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740, 23328547||Erlotinib:NCCN||Erlotinib:PMID: 27102076;Erlotinib:PMID: 27102076||Gefitinib:PMID: 24950987||Lapatinib:PMID: 22885469||novel EGFR mAb inhibitors:PMID: 25962717;Panitumumab:PMID: 22270724||Osimertinib:PMID: 26515464||Rindopepimut:NCT01480479	Afatinib:.||Afatinib:.||Afatinib:NCCN;EGFR inhibitor 1st gens:PMID: 19680293;EGFR inhibitor 2nd gens:PMID: 22452896;Erlotinib:NCCN;Erlotinib:.;Gefitinib:.;Lapatinib:.||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827;Cetuximab:PMID: 25623215;Panitumumab:PMID: 26059438||Cetuximab:PMID: 25623215||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 25623215||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||EGFR inhibitor 3rd gens:PMID: 25939061||EGFR inhibitor 1st gens:PMID: 19680293;Erlotinib:PMID: 19680293||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:PMID: 26773740||Erlotinib:ASCO2015(abstre19028);Gefitinib:PMID: 21274259, 22261807||Gefitinib:PMID: 21274259||Gefitinib:PMID: 21274259||Osimertinib:ASCO 2017 (abstr 2572)||Osimertinib:ASCO 2017 (abstr 2572)||Panitumumab:FDA guidelines||Rociletinib:PMID: 27283993
EGFR	amp	0.40%		28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Erlotinib:NCCN;Erlotinib:FDA;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728;Osimertinib:NCT02465060||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Erlotinib:NCCN;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:PMID: 27553514;Afatinib + Cetuximab:PMID: 25074459;Afatinib + Nimotuzumab:PMID: 26667485;AZD9291:PMID: 25939061;AZD9291:PMID: 26473643;EGFR inhibitor 3rd gens:ASCO 2014 (abstr 8009),ENA 2014 (abstr 10LBA),ENA 2014 (abstr 9LBA),ASCO 2015 (abstr 8001);Erlotinib:PMID: 21430269;Erlotinib:PMID: 24781527;Gefitinib:PMID: 18509184;Gefitinib:PMID: 20686428;Gefitinib:PMID: 20871262;Gefitinib:PMID: 21030498;Gefitinib:PMID: 22215752;Gefitinib:PMID: 22815900;Gefitinib:PMID: 23180674;Gefitinib:PMID: 23407566;Gefitinib:PMID: 23886554;HM61713:NCT02322281;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728;Osimertinib:FDA;Rociletinib:NCT02322281;Tyrosine kinase inhibitor - NS:PMID: 22773810;Tyrosine kinase inhibitor - NS:PMID: 25939061;Tyrosine kinase inhibitor - NS:PMID: 23542356;Tyrosine kinase inhibitor - NS:PMID: 24035188||Afatinib:FDA;Erlotinib:FDA;Gefitinib:FDA;Osimertinib:NCT02465060||Afatinib:PMID: 22753918, 25589191;Afatinib:ESMO 2012 (abstr 1289);Cetuximab:ESMO 2012 (abstr 1289);Erlotinib:PMID: 22190593||AZD9291:PMID: 25939061||Cetuximab:PMID: 23578570||Cetuximab:FDA||Cetuximab + Sirolimus:PMID: 24934779||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740||Erlotinib:PMID: 17177598||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740, 23328547||Erlotinib:NCCN||Erlotinib:PMID: 27102076;Erlotinib:PMID: 27102076||Gefitinib:PMID: 24950987||Lapatinib:PMID: 22885469||novel EGFR mAb inhibitors:PMID: 25962717;Panitumumab:PMID: 22270724||Osimertinib:PMID: 26515464||Rindopepimut:NCT01480479	Afatinib:.||Afatinib:.||Afatinib:NCCN;EGFR inhibitor 1st gens:PMID: 19680293;EGFR inhibitor 2nd gens:PMID: 22452896;Erlotinib:NCCN;Erlotinib:.;Gefitinib:.;Lapatinib:.||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827;Cetuximab:PMID: 25623215;Panitumumab:PMID: 26059438||Cetuximab:PMID: 25623215||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 25623215||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||EGFR inhibitor 3rd gens:PMID: 25939061||EGFR inhibitor 1st gens:PMID: 19680293;Erlotinib:PMID: 19680293||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:PMID: 26773740||Erlotinib:ASCO2015(abstre19028);Gefitinib:PMID: 21274259, 22261807||Gefitinib:PMID: 21274259||Gefitinib:PMID: 21274259||Osimertinib:ASCO 2017 (abstr 2572)||Osimertinib:ASCO 2017 (abstr 2572)||Panitumumab:FDA guidelines||Rociletinib:PMID: 27283993
EGFR	mut	0.40%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Erlotinib:NCCN;Erlotinib:FDA;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728;Osimertinib:NCT02465060||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:FDA;Afatinib + Cetuximab:ESMO 2012 (abstr 1289);EGFR TK inhibitors:PMID: 22753918;Erlotinib:NCCN;Gefitinib:FDA;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728||Afatinib:PMID: 27553514;Afatinib + Cetuximab:PMID: 25074459;Afatinib + Nimotuzumab:PMID: 26667485;AZD9291:PMID: 25939061;AZD9291:PMID: 26473643;EGFR inhibitor 3rd gens:ASCO 2014 (abstr 8009),ENA 2014 (abstr 10LBA),ENA 2014 (abstr 9LBA),ASCO 2015 (abstr 8001);Erlotinib:PMID: 21430269;Erlotinib:PMID: 24781527;Gefitinib:PMID: 18509184;Gefitinib:PMID: 20686428;Gefitinib:PMID: 20871262;Gefitinib:PMID: 21030498;Gefitinib:PMID: 22215752;Gefitinib:PMID: 22815900;Gefitinib:PMID: 23180674;Gefitinib:PMID: 23407566;Gefitinib:PMID: 23886554;HM61713:NCT02322281;HSP90 inhibitors:ESMO 2012 (abstr 4380);MEK inhibitor (alone or in combination)s:PMID: 23102728;Osimertinib:FDA;Rociletinib:NCT02322281;Tyrosine kinase inhibitor - NS:PMID: 22773810;Tyrosine kinase inhibitor - NS:PMID: 25939061;Tyrosine kinase inhibitor - NS:PMID: 23542356;Tyrosine kinase inhibitor - NS:PMID: 24035188||Afatinib:FDA;Erlotinib:FDA;Gefitinib:FDA;Osimertinib:NCT02465060||Afatinib:PMID: 22753918, 25589191;Afatinib:ESMO 2012 (abstr 1289);Cetuximab:ESMO 2012 (abstr 1289);Erlotinib:PMID: 22190593||AZD9291:PMID: 25939061||Cetuximab:PMID: 23578570||Cetuximab:FDA||Cetuximab + Sirolimus:PMID: 24934779||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740||Erlotinib:PMID: 17177598||Erlotinib:PMID: 17177598||Erlotinib:PMID: 26773740, 23328547||Erlotinib:NCCN||Erlotinib:PMID: 27102076;Erlotinib:PMID: 27102076||Gefitinib:PMID: 24950987||Lapatinib:PMID: 22885469||novel EGFR mAb inhibitors:PMID: 25962717;Panitumumab:PMID: 22270724||Osimertinib:PMID: 26515464||Rindopepimut:NCT01480479	Afatinib:.||Afatinib:.||Afatinib:NCCN;EGFR inhibitor 1st gens:PMID: 19680293;EGFR inhibitor 2nd gens:PMID: 22452896;Erlotinib:NCCN;Erlotinib:.;Gefitinib:.;Lapatinib:.||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827;Cetuximab:PMID: 25623215;Panitumumab:PMID: 26059438||Cetuximab:PMID: 25623215||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 25623215||Cetuximab:PMID: 22270724, 26059438, 25623215, 22270724, 26888827||Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||EGFR inhibitor 3rd gens:PMID: 25939061||EGFR inhibitor 1st gens:PMID: 19680293;Erlotinib:PMID: 19680293||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:.;Gefitinib:.;Lapatinib:.||Erlotinib:PMID: 26773740||Erlotinib:ASCO2015(abstre19028);Gefitinib:PMID: 21274259, 22261807||Gefitinib:PMID: 21274259||Gefitinib:PMID: 21274259||Osimertinib:ASCO 2017 (abstr 2572)||Osimertinib:ASCO 2017 (abstr 2572)||Panitumumab:FDA guidelines||Rociletinib:PMID: 27283993
KRAS	mut	1.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	Abemaciclib:PMID: 27217383;BCL2 inhibitor:PMID: 25968887;Decitabine:PMID: 25968887;Gemcitabine:PMID: 23583440;MEK inhibitor:PMID: 23583440;MEK inhibitor:PMID: 25294897;Ponatinib:PMID: 27338794;Regorafenib:FDA guidelines;Selumetinib:NCT00890825;Sorafenib:PMID: 25294897;Trametinib:PMID: 27338794	Cetuximab:PMID: 27114605;Cetuximab:PMID: 27114605||Cetuximab:FDA guidelines;Lapatinib:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Panitumumab:FDA guidelines;Selumetinib:PMID: 26802155;Trastuzumab:ASCO 2015 (abstr 3508),NCT01104571,EBCC10||Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996||Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996||Imatinib:PMID: 24687822
KRAS		19.00%		26405193	research	8.39	2015	19		Abemaciclib:PMID: 27217383;BCL2 inhibitor:PMID: 25968887;Decitabine:PMID: 25968887;Gemcitabine:PMID: 23583440;MEK inhibitor:PMID: 23583440;MEK inhibitor:PMID: 25294897;Ponatinib:PMID: 27338794;Regorafenib:FDA guidelines;Selumetinib:NCT00890825;Sorafenib:PMID: 25294897;Trametinib:PMID: 27338794	Cetuximab:PMID: 27114605;Cetuximab:PMID: 27114605||Cetuximab:FDA guidelines;Lapatinib:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Panitumumab:FDA guidelines;Selumetinib:PMID: 26802155;Trastuzumab:ASCO 2015 (abstr 3508),NCT01104571,EBCC10||Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996||Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996||Imatinib:PMID: 24687822
KRAS	mut	16.50%	RAS/RAF kinase	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Abemaciclib:PMID: 27217383;BCL2 inhibitor:PMID: 25968887;Decitabine:PMID: 25968887;Gemcitabine:PMID: 23583440;MEK inhibitor:PMID: 23583440;MEK inhibitor:PMID: 25294897;Ponatinib:PMID: 27338794;Regorafenib:FDA guidelines;Selumetinib:NCT00890825;Sorafenib:PMID: 25294897;Trametinib:PMID: 27338794	Cetuximab:PMID: 27114605;Cetuximab:PMID: 27114605||Cetuximab:FDA guidelines;Lapatinib:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Panitumumab:FDA guidelines;Selumetinib:PMID: 26802155;Trastuzumab:ASCO 2015 (abstr 3508),NCT01104571,EBCC10||Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996||Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996||Imatinib:PMID: 24687822
KRAS	mut	5.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	Abemaciclib:PMID: 27217383;BCL2 inhibitor:PMID: 25968887;Decitabine:PMID: 25968887;Gemcitabine:PMID: 23583440;MEK inhibitor:PMID: 23583440;MEK inhibitor:PMID: 25294897;Ponatinib:PMID: 27338794;Regorafenib:FDA guidelines;Selumetinib:NCT00890825;Sorafenib:PMID: 25294897;Trametinib:PMID: 27338794	Cetuximab:PMID: 27114605;Cetuximab:PMID: 27114605||Cetuximab:FDA guidelines;Lapatinib:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Panitumumab:FDA guidelines;Selumetinib:PMID: 26802155;Trastuzumab:ASCO 2015 (abstr 3508),NCT01104571,EBCC10||Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996||Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996||Imatinib:PMID: 24687822
KRAS		10.30%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	Abemaciclib:PMID: 27217383;BCL2 inhibitor:PMID: 25968887;Decitabine:PMID: 25968887;Gemcitabine:PMID: 23583440;MEK inhibitor:PMID: 23583440;MEK inhibitor:PMID: 25294897;Ponatinib:PMID: 27338794;Regorafenib:FDA guidelines;Selumetinib:NCT00890825;Sorafenib:PMID: 25294897;Trametinib:PMID: 27338794	Cetuximab:PMID: 27114605;Cetuximab:PMID: 27114605||Cetuximab:FDA guidelines;Lapatinib:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Panitumumab:FDA guidelines;Selumetinib:PMID: 26802155;Trastuzumab:ASCO 2015 (abstr 3508),NCT01104571,EBCC10||Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996||Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996||Imatinib:PMID: 24687822
MET	(STV)CNV	2.3%(5/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	Cabozantinib:ENA 2015 (abstr A52);Crizotinib:NCT02499614,ASCO 2015 (abstr 2595);Crizotinib:ASCO 2014 (abstr 8001),ASCO 2015 (abstr 2595),ASCO GI 2015 (abstr 1);Crizotinib:PMID: 22162573;Panitumumab:ENA 2015 (abstr A52)||Crizotinib:AACR 2012 (abstr 1786)||Crizotinib:PMID: 17483355;MET inhibitors:PMID: 23213094||Crizotinib:PMID: 17483355;MET inhibitors:PMID: 23610116||Crizotinib:PMID: 17483355||Crizotinib:PMID: 17483355||Crizotinib:PMID: 17483355||Crizotinib:PMID: 27325282;Vemurafenib:PMID: 27325282||Crizotinib:PMID: 26432108;Trastuzumab:PMID: 26432108||Crizotinib:PMID: 27748748||Crizotinib:AACR 2016 (abstr CT2006)||Savolitinib:PMID: 28644771	Crizotinib:PMID: 17483355||Lapatinib:PMID: 22238368;Trastuzumab:PMID: 22850551;Trastuzumab:PMID: 22850551, PMID: 26432108||Osimertinib:PMID: 27252416;Rociletinib:PMID: 27252416||Panitumumab:PMID: 27325282;Vemurafenib:PMID: 27325282
MET	amp	1.00%	PI3K/AKT/MTOR pathway	27262756	Review	7.43	2016	12		Cabozantinib:ENA 2015 (abstr A52);Crizotinib:NCT02499614,ASCO 2015 (abstr 2595);Crizotinib:ASCO 2014 (abstr 8001),ASCO 2015 (abstr 2595),ASCO GI 2015 (abstr 1);Crizotinib:PMID: 22162573;Panitumumab:ENA 2015 (abstr A52)||Crizotinib:AACR 2012 (abstr 1786)||Crizotinib:PMID: 17483355;MET inhibitors:PMID: 23213094||Crizotinib:PMID: 17483355;MET inhibitors:PMID: 23610116||Crizotinib:PMID: 17483355||Crizotinib:PMID: 17483355||Crizotinib:PMID: 17483355||Crizotinib:PMID: 27325282;Vemurafenib:PMID: 27325282||Crizotinib:PMID: 26432108;Trastuzumab:PMID: 26432108||Crizotinib:PMID: 27748748||Crizotinib:AACR 2016 (abstr CT2006)||Savolitinib:PMID: 28644771	Crizotinib:PMID: 17483355||Lapatinib:PMID: 22238368;Trastuzumab:PMID: 22850551;Trastuzumab:PMID: 22850551, PMID: 26432108||Osimertinib:PMID: 27252416;Rociletinib:PMID: 27252416||Panitumumab:PMID: 27325282;Vemurafenib:PMID: 27325282
MET	amp	1.70%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	Cabozantinib:ENA 2015 (abstr A52);Crizotinib:NCT02499614,ASCO 2015 (abstr 2595);Crizotinib:ASCO 2014 (abstr 8001),ASCO 2015 (abstr 2595),ASCO GI 2015 (abstr 1);Crizotinib:PMID: 22162573;Panitumumab:ENA 2015 (abstr A52)||Crizotinib:AACR 2012 (abstr 1786)||Crizotinib:PMID: 17483355;MET inhibitors:PMID: 23213094||Crizotinib:PMID: 17483355;MET inhibitors:PMID: 23610116||Crizotinib:PMID: 17483355||Crizotinib:PMID: 17483355||Crizotinib:PMID: 17483355||Crizotinib:PMID: 27325282;Vemurafenib:PMID: 27325282||Crizotinib:PMID: 26432108;Trastuzumab:PMID: 26432108||Crizotinib:PMID: 27748748||Crizotinib:AACR 2016 (abstr CT2006)||Savolitinib:PMID: 28644771	Crizotinib:PMID: 17483355||Lapatinib:PMID: 22238368;Trastuzumab:PMID: 22850551;Trastuzumab:PMID: 22850551, PMID: 26432108||Osimertinib:PMID: 27252416;Rociletinib:PMID: 27252416||Panitumumab:PMID: 27325282;Vemurafenib:PMID: 27325282
MET	amp,mut	1.30%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Cabozantinib:ENA 2015 (abstr A52);Crizotinib:NCT02499614,ASCO 2015 (abstr 2595);Crizotinib:ASCO 2014 (abstr 8001),ASCO 2015 (abstr 2595),ASCO GI 2015 (abstr 1);Crizotinib:PMID: 22162573;Panitumumab:ENA 2015 (abstr A52)||Crizotinib:AACR 2012 (abstr 1786)||Crizotinib:PMID: 17483355;MET inhibitors:PMID: 23213094||Crizotinib:PMID: 17483355;MET inhibitors:PMID: 23610116||Crizotinib:PMID: 17483355||Crizotinib:PMID: 17483355||Crizotinib:PMID: 17483355||Crizotinib:PMID: 27325282;Vemurafenib:PMID: 27325282||Crizotinib:PMID: 26432108;Trastuzumab:PMID: 26432108||Crizotinib:PMID: 27748748||Crizotinib:AACR 2016 (abstr CT2006)||Savolitinib:PMID: 28644771	Crizotinib:PMID: 17483355||Lapatinib:PMID: 22238368;Trastuzumab:PMID: 22850551;Trastuzumab:PMID: 22850551, PMID: 26432108||Osimertinib:PMID: 27252416;Rociletinib:PMID: 27252416||Panitumumab:PMID: 27325282;Vemurafenib:PMID: 27325282
MET	amp	0.50%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Cabozantinib:ENA 2015 (abstr A52);Crizotinib:NCT02499614,ASCO 2015 (abstr 2595);Crizotinib:ASCO 2014 (abstr 8001),ASCO 2015 (abstr 2595),ASCO GI 2015 (abstr 1);Crizotinib:PMID: 22162573;Panitumumab:ENA 2015 (abstr A52)||Crizotinib:AACR 2012 (abstr 1786)||Crizotinib:PMID: 17483355;MET inhibitors:PMID: 23213094||Crizotinib:PMID: 17483355;MET inhibitors:PMID: 23610116||Crizotinib:PMID: 17483355||Crizotinib:PMID: 17483355||Crizotinib:PMID: 17483355||Crizotinib:PMID: 27325282;Vemurafenib:PMID: 27325282||Crizotinib:PMID: 26432108;Trastuzumab:PMID: 26432108||Crizotinib:PMID: 27748748||Crizotinib:AACR 2016 (abstr CT2006)||Savolitinib:PMID: 28644771	Crizotinib:PMID: 17483355||Lapatinib:PMID: 22238368;Trastuzumab:PMID: 22850551;Trastuzumab:PMID: 22850551, PMID: 26432108||Osimertinib:PMID: 27252416;Rociletinib:PMID: 27252416||Panitumumab:PMID: 27325282;Vemurafenib:PMID: 27325282
PBRM1	mut	6.50%	Epigenetic modifiers,	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Everolimus:PMID: 25997916	None
PBRM1	mut	21.00%	chromatin remodeling	28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	Everolimus:PMID: 25997916	None
PBRM1	mut	21.00%	chromatin remodeling	28297679		8.4	2017	8	仅在第一阶段出现	Everolimus:PMID: 25997916	None
PBRM1	mut	17.00%		24185509	research	24.17	2013	164	32 iCC，9 gall-bladder carcinomas	Everolimus:PMID: 25997916	None
PBRM1		10.30%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	Everolimus:PMID: 25997916	None
VEGFA	amp	1.00%	PI3K/AKT/MTOR pathway,MAP kinase pathway	27262756	Review	7.43	2016	12		Sorafenib:PMID: 24687604	None
VEGFA	amp	8.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	Sorafenib:PMID: 24687604	None
VEGFA	mut	0.90%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Sorafenib:PMID: 24687604	None
VEGFA	amp	17/547 (3.1)*	VEGF signalling	26099984	Review	4.91	2015	86		Sorafenib:PMID: 24687604	None
VEGFA	amp	7-11%	Ras/raf/mapk,Akt/mtor	26099527	Review	7.67	2015	77		Sorafenib:PMID: 24687604	None
ARID1B	mut	11.1%（3/27）；		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
ARID1B	mut	1.30%	chromatin remodeling	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
ARID1B	mut	5.00%		28297679		8.4	2017	8	仅在第一阶段出现	None	None
ARID1B	mut	6.7%(8/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
CDKN1A	mut	2.10%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
CDKN1A	mut	2.10%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
CDKN1A	mut	3.00%		28297679		8.4	2017	8	仅在第一阶段出现	None	None
CDKN1A	mut	1.80%	p53-Rb pathway	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
ERBB2	mut	0.40%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Abemaciclib:PMID: 26658964;Anastrozole:FDA;Everolimus:FDA;Exemestane:FDA;Fulvestrant:FDA;Letrozole:FDA;LHRH analogues or antagonist:FDA;Palbociclib:FDA;Tamoxifen:FDA||Afatinib:AACR 2014 (abstr CT228);Afatinib:PMID: 20142587, 22418700, 23632474;Afatinib:PMID: 27044931;Everolimus:PMID: 21107682, 20975068;HSP90 inhibitor:PMID: 21558407;Lapatinib:FDA;Lapatinib:PMID: 26022204;Lapatinib:PMID: 25694417,NCT02015169;Lapatinib:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Lapatinib:PMID: 25294905;Neratinib:PMID: 20142587, 22418700, 23632474;Pertuzumab:PMID: 24960402;Pertuzumab:FDA;Pertuzumab:PMID: 26022204;Trastuzumab:FDA;Trastuzumab:FDA;Trastuzumab:PMID: 26022204;Trastuzumab:PMID: 21380780;Trastuzumab:PMID: 20003286, 12525520;Trastuzumab:PMID: 21107682, 20975068;Trastuzumab:PMID: 21558407;Trastuzumab:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Trastuzumab:PMID: 25294905;Trastuzumab:http: //ascopubs.org/doi/full/10.1200/PO.16.00055||Afatinib:PMID: 26598547;Afatinib:PMID: 26598547,ASCO 2017 (abstr 9071);Lapatinib:PMID: 26598547;Lapatinib:PMID: 26598547,ASCO 2017 (abstr 9071);Neratinib:PMID: 26598547;Neratinib:PMID: 26598547,ASCO 2017 (abstr 9071);Trastuzumab:PMID: 26598547;Trastuzumab:PMID: 26598547,ASCO 2017 (abstr 9071)||Crizotinib:PMID: 26432108;Trastuzumab:PMID: 26432108||Dacomitinib:PMID: 25899785;Neratinib:ESMO 2014 (abstr LBA39_PR);Tensirolimus:ESMO 2014 (abstr LBA39_PR)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23950206||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:FDA;MK2206:ASCO 2013 (abstr 2605), 26104654;Pertuzumab:FDA;Trastuzumab:ASCO 2013 (abstr 2605), 26104654;Trastuzumab:FDA;Trastuzumab:FDA||Neratinib:PMID: 27697991||Neratinib:PMID: 23220880||Neratinib:PMID: 23220880||Neratinib:AACR 2017 (abstr CT001)||Neratinib:AACR 2017 (abstr CT001)||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 22908275||Trastuzumab:PMID: 22908275||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 16775247||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:ASCO 2017 (abstr 8510)	Lapatinib:PMID: 27697991||Lapatinib:PMID: 22238368;Trastuzumab:PMID: 22850551;Trastuzumab:PMID: 22850551, PMID: 26432108||Osimertinib:PMID: 27252416;Rociletinib:PMID: 27252416;Trastuzumab:PMID: 26099744, 19840887||Tak-285:PMID: 26439378||Trastuzumab:PMID: 22850551
ERBB2	mut	3.70%		28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Abemaciclib:PMID: 26658964;Anastrozole:FDA;Everolimus:FDA;Exemestane:FDA;Fulvestrant:FDA;Letrozole:FDA;LHRH analogues or antagonist:FDA;Palbociclib:FDA;Tamoxifen:FDA||Afatinib:AACR 2014 (abstr CT228);Afatinib:PMID: 20142587, 22418700, 23632474;Afatinib:PMID: 27044931;Everolimus:PMID: 21107682, 20975068;HSP90 inhibitor:PMID: 21558407;Lapatinib:FDA;Lapatinib:PMID: 26022204;Lapatinib:PMID: 25694417,NCT02015169;Lapatinib:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Lapatinib:PMID: 25294905;Neratinib:PMID: 20142587, 22418700, 23632474;Pertuzumab:PMID: 24960402;Pertuzumab:FDA;Pertuzumab:PMID: 26022204;Trastuzumab:FDA;Trastuzumab:FDA;Trastuzumab:PMID: 26022204;Trastuzumab:PMID: 21380780;Trastuzumab:PMID: 20003286, 12525520;Trastuzumab:PMID: 21107682, 20975068;Trastuzumab:PMID: 21558407;Trastuzumab:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Trastuzumab:PMID: 25294905;Trastuzumab:http: //ascopubs.org/doi/full/10.1200/PO.16.00055||Afatinib:PMID: 26598547;Afatinib:PMID: 26598547,ASCO 2017 (abstr 9071);Lapatinib:PMID: 26598547;Lapatinib:PMID: 26598547,ASCO 2017 (abstr 9071);Neratinib:PMID: 26598547;Neratinib:PMID: 26598547,ASCO 2017 (abstr 9071);Trastuzumab:PMID: 26598547;Trastuzumab:PMID: 26598547,ASCO 2017 (abstr 9071)||Crizotinib:PMID: 26432108;Trastuzumab:PMID: 26432108||Dacomitinib:PMID: 25899785;Neratinib:ESMO 2014 (abstr LBA39_PR);Tensirolimus:ESMO 2014 (abstr LBA39_PR)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23950206||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:FDA;MK2206:ASCO 2013 (abstr 2605), 26104654;Pertuzumab:FDA;Trastuzumab:ASCO 2013 (abstr 2605), 26104654;Trastuzumab:FDA;Trastuzumab:FDA||Neratinib:PMID: 27697991||Neratinib:PMID: 23220880||Neratinib:PMID: 23220880||Neratinib:AACR 2017 (abstr CT001)||Neratinib:AACR 2017 (abstr CT001)||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 22908275||Trastuzumab:PMID: 22908275||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 16775247||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:ASCO 2017 (abstr 8510)	Lapatinib:PMID: 27697991||Lapatinib:PMID: 22238368;Trastuzumab:PMID: 22850551;Trastuzumab:PMID: 22850551, PMID: 26432108||Osimertinib:PMID: 27252416;Rociletinib:PMID: 27252416;Trastuzumab:PMID: 26099744, 19840887||Tak-285:PMID: 26439378||Trastuzumab:PMID: 22850551
ERBB2	amp	3.9-8.5%		28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Abemaciclib:PMID: 26658964;Anastrozole:FDA;Everolimus:FDA;Exemestane:FDA;Fulvestrant:FDA;Letrozole:FDA;LHRH analogues or antagonist:FDA;Palbociclib:FDA;Tamoxifen:FDA||Afatinib:AACR 2014 (abstr CT228);Afatinib:PMID: 20142587, 22418700, 23632474;Afatinib:PMID: 27044931;Everolimus:PMID: 21107682, 20975068;HSP90 inhibitor:PMID: 21558407;Lapatinib:FDA;Lapatinib:PMID: 26022204;Lapatinib:PMID: 25694417,NCT02015169;Lapatinib:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Lapatinib:PMID: 25294905;Neratinib:PMID: 20142587, 22418700, 23632474;Pertuzumab:PMID: 24960402;Pertuzumab:FDA;Pertuzumab:PMID: 26022204;Trastuzumab:FDA;Trastuzumab:FDA;Trastuzumab:PMID: 26022204;Trastuzumab:PMID: 21380780;Trastuzumab:PMID: 20003286, 12525520;Trastuzumab:PMID: 21107682, 20975068;Trastuzumab:PMID: 21558407;Trastuzumab:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Trastuzumab:PMID: 25294905;Trastuzumab:http: //ascopubs.org/doi/full/10.1200/PO.16.00055||Afatinib:PMID: 26598547;Afatinib:PMID: 26598547,ASCO 2017 (abstr 9071);Lapatinib:PMID: 26598547;Lapatinib:PMID: 26598547,ASCO 2017 (abstr 9071);Neratinib:PMID: 26598547;Neratinib:PMID: 26598547,ASCO 2017 (abstr 9071);Trastuzumab:PMID: 26598547;Trastuzumab:PMID: 26598547,ASCO 2017 (abstr 9071)||Crizotinib:PMID: 26432108;Trastuzumab:PMID: 26432108||Dacomitinib:PMID: 25899785;Neratinib:ESMO 2014 (abstr LBA39_PR);Tensirolimus:ESMO 2014 (abstr LBA39_PR)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23950206||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:FDA;MK2206:ASCO 2013 (abstr 2605), 26104654;Pertuzumab:FDA;Trastuzumab:ASCO 2013 (abstr 2605), 26104654;Trastuzumab:FDA;Trastuzumab:FDA||Neratinib:PMID: 27697991||Neratinib:PMID: 23220880||Neratinib:PMID: 23220880||Neratinib:AACR 2017 (abstr CT001)||Neratinib:AACR 2017 (abstr CT001)||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 22908275||Trastuzumab:PMID: 22908275||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 16775247||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:ASCO 2017 (abstr 8510)	Lapatinib:PMID: 27697991||Lapatinib:PMID: 22238368;Trastuzumab:PMID: 22850551;Trastuzumab:PMID: 22850551, PMID: 26432108||Osimertinib:PMID: 27252416;Rociletinib:PMID: 27252416;Trastuzumab:PMID: 26099744, 19840887||Tak-285:PMID: 26439378||Trastuzumab:PMID: 22850551
ERBB2	mut	3.00%		28297679		8.4	2017	8	仅在第一阶段出现	Abemaciclib:PMID: 26658964;Anastrozole:FDA;Everolimus:FDA;Exemestane:FDA;Fulvestrant:FDA;Letrozole:FDA;LHRH analogues or antagonist:FDA;Palbociclib:FDA;Tamoxifen:FDA||Afatinib:AACR 2014 (abstr CT228);Afatinib:PMID: 20142587, 22418700, 23632474;Afatinib:PMID: 27044931;Everolimus:PMID: 21107682, 20975068;HSP90 inhibitor:PMID: 21558407;Lapatinib:FDA;Lapatinib:PMID: 26022204;Lapatinib:PMID: 25694417,NCT02015169;Lapatinib:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Lapatinib:PMID: 25294905;Neratinib:PMID: 20142587, 22418700, 23632474;Pertuzumab:PMID: 24960402;Pertuzumab:FDA;Pertuzumab:PMID: 26022204;Trastuzumab:FDA;Trastuzumab:FDA;Trastuzumab:PMID: 26022204;Trastuzumab:PMID: 21380780;Trastuzumab:PMID: 20003286, 12525520;Trastuzumab:PMID: 21107682, 20975068;Trastuzumab:PMID: 21558407;Trastuzumab:ASCO 2015 (abstr 3508),NCT01104571,EBCC10;Trastuzumab:PMID: 25294905;Trastuzumab:http: //ascopubs.org/doi/full/10.1200/PO.16.00055||Afatinib:PMID: 26598547;Afatinib:PMID: 26598547,ASCO 2017 (abstr 9071);Lapatinib:PMID: 26598547;Lapatinib:PMID: 26598547,ASCO 2017 (abstr 9071);Neratinib:PMID: 26598547;Neratinib:PMID: 26598547,ASCO 2017 (abstr 9071);Trastuzumab:PMID: 26598547;Trastuzumab:PMID: 26598547,ASCO 2017 (abstr 9071)||Crizotinib:PMID: 26432108;Trastuzumab:PMID: 26432108||Dacomitinib:PMID: 25899785;Neratinib:ESMO 2014 (abstr LBA39_PR);Tensirolimus:ESMO 2014 (abstr LBA39_PR)||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708||Everolimus:PMID: 27091708;Trastuzumab:PMID: 27091708||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880;Trastuzumab:PMID: 23220880, 22908275||Lapatinib:PMID: 23950206||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:PMID: 23220880;Neratinib:PMID: 23220880||Lapatinib:FDA;MK2206:ASCO 2013 (abstr 2605), 26104654;Pertuzumab:FDA;Trastuzumab:ASCO 2013 (abstr 2605), 26104654;Trastuzumab:FDA;Trastuzumab:FDA||Neratinib:PMID: 27697991||Neratinib:PMID: 23220880||Neratinib:PMID: 23220880||Neratinib:AACR 2017 (abstr CT001)||Neratinib:AACR 2017 (abstr CT001)||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 22908275||Trastuzumab:PMID: 22908275||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 16775247||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:PMID: 22908275;Trastuzumab:PMID: 23220880, 22908275||Trastuzumab:ASCO 2017 (abstr 8510)	Lapatinib:PMID: 27697991||Lapatinib:PMID: 22238368;Trastuzumab:PMID: 22850551;Trastuzumab:PMID: 22850551, PMID: 26432108||Osimertinib:PMID: 27252416;Rociletinib:PMID: 27252416;Trastuzumab:PMID: 26099744, 19840887||Tak-285:PMID: 26439378||Trastuzumab:PMID: 22850551
JAK1	mut	1.00%	JAK/STAT signalling	27262756	Review	7.43	2016	12		Ruxolitinib:PMID: 22955920, 18805579	None
JAK1	mut	0.40%	PI3K/AKT/MTOR pathway,IL6/JAK/STAT pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Ruxolitinib:PMID: 22955920, 18805579	None
JAK1	mut	0.90%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Ruxolitinib:PMID: 22955920, 18805579	None
JAK1	mut	14/928 (1.5)	JAK/STAT signalling	26099984	Review	4.91	2015	86		Ruxolitinib:PMID: 22955920, 18805579	None
TSC1	mut	3.00%	PI3K/MTOR signalling	27262756	Review	7.43	2016	12		Everolimus:PMID: 22923433;Temsirolimus:PMID: 22923433||Everolimus or Temsirolimus:PMID: 24622468,ASCO 2015 (abstr 11010),ASCO 2015 (abstr 4519)||Everolimus or Temsirolimus:PMID: 22923433;Everolimus or Temsirolimus:FDA;Everolimus or Temsirolimus:PMID: 26859683;Everolimus or Temsirolimus:FDA;Everolimus or Temsirolimus:PMID: 24622468, 26859683,ASCO 2015 (abstr 11010),ASCO 2015 (abstr 4519)	None
TSC1	mut,homo del	2.60%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Everolimus:PMID: 22923433;Temsirolimus:PMID: 22923433||Everolimus or Temsirolimus:PMID: 24622468,ASCO 2015 (abstr 11010),ASCO 2015 (abstr 4519)||Everolimus or Temsirolimus:PMID: 22923433;Everolimus or Temsirolimus:FDA;Everolimus or Temsirolimus:PMID: 26859683;Everolimus or Temsirolimus:FDA;Everolimus or Temsirolimus:PMID: 24622468, 26859683,ASCO 2015 (abstr 11010),ASCO 2015 (abstr 4519)	None
TSC1	mut	3-8%	Ras/raf/mapk	26099527	Review	7.67	2015	77		Everolimus:PMID: 22923433;Temsirolimus:PMID: 22923433||Everolimus or Temsirolimus:PMID: 24622468,ASCO 2015 (abstr 11010),ASCO 2015 (abstr 4519)||Everolimus or Temsirolimus:PMID: 22923433;Everolimus or Temsirolimus:FDA;Everolimus or Temsirolimus:PMID: 26859683;Everolimus or Temsirolimus:FDA;Everolimus or Temsirolimus:PMID: 24622468, 26859683,ASCO 2015 (abstr 11010),ASCO 2015 (abstr 4519)	None
TSC1	del，mut	2.00%	PIK3-mTOR	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Everolimus:PMID: 22923433;Temsirolimus:PMID: 22923433||Everolimus or Temsirolimus:PMID: 24622468,ASCO 2015 (abstr 11010),ASCO 2015 (abstr 4519)||Everolimus or Temsirolimus:PMID: 22923433;Everolimus or Temsirolimus:FDA;Everolimus or Temsirolimus:PMID: 26859683;Everolimus or Temsirolimus:FDA;Everolimus or Temsirolimus:PMID: 24622468, 26859683,ASCO 2015 (abstr 11010),ASCO 2015 (abstr 4519)	None
BAZ2B	mut	3.00%		27838634	Review	5.03	2017	8		None	None
BAZ2B	mut	11.1%（3/27）；1.6%(2/120)		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
BAZ2B	mut	1.6%(2/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
BRAF		5.00%		26405193	research	8.39	2015	19		BRAF inhibitors:PMID: 23715574;Trametinib:PMID: 23248257, 22805292, 23248257||BRAF inhibitors:PMID: 22608338;BRAF inhibitors:PMID: 22038996, 22586120;BRAF inhibitor + CDK2/4 inhibitors:PMID: 22997239;BRAF inhibitor + HSP90 inhibitors:PMID: 22351686;BRAF inhibitor + MEK inhibitors:ASCO 2013 (abstr 9029);BRAF inhibitor + PI3K pathway inhibitors:PMID: 22389471, 21156289;Cobimetinib:FDA;Dabrafenib:PMID: 23470635, 22608338;Dabrafenib:PMID: 23470635, 22608338;Dabrafenib:PMID: 23524406, 22608338,ASCO 2013 (abstr 8009),ESMO 2014 (abstr LBA38_PR), 20818844, 23489023, 27080216;Dabrafenib:FDA;Dabrafenib:NCCN;Dabrafenib + Trametinib:PMID: 27048246;Dabrafenib + Trametinib:PMID: 26392102,ASCO 2015 (abstr 8006);Dabrafenib + Trametinib:PMID: 27283860;Dabrafenib + Trametinib:FDA;ERK inhibitors:PMID: 23614898, 22997239;Ipilimumab:PMID: 22382362, 23709751;MEK inhibitors:PMID: 22241789;MEK inhibitors:PMID: 19018267;Panitumumab + Dabrafenib + Trametinib:ASCO 2014 (abstr 3515),ASCO 2015 (abstr 103);Pan-RAF inhibitors:ESMO 2015 (abstract 300),AACR 2016 (abstr CT005);PLX4720:PMC3638050;Selumetinib:NCT01089101;Trametinib:FDA;Vandetanib:PMID: 20065189, 22025146;Vemurafenib:PMID: 22743296, 22621641, 23612012;Vemurafenib:PMID: 22586120;Vemurafenib:PMID: 22608338, 20818844, 23489023;Vemurafenib:FDA;Vemurafenib:PMID: 26287849;Vemurafenib + Cobimetinib:FDA||BYL719:ENA 2014 (abstr 11LBA);Cetuximab:PMID: 27729313;Dabrafenib:ENA 2014 (abstr 11LBA);Irinotecan:PMID: 27729313;Panitumumab:ENA 2014 (abstr 11LBA);Vemurafenib:PMID: 27729313||Cobimetinib:FDA;Dabrafenib + Trametinib:FDA;Ipilimumab:PMID: 22382362, 23709751;Trametinib:FDA;Vemurafenib:NCCN;Vemurafenib:PMID: 26287849;Vemurafenib + Cobimetinib:FDA||Crizotinib:PMID: 27325282;Vemurafenib:PMID: 27325282||Dabrafenib:PMID: 23237741;Ipilimumab:PMID: 22382362, 23709751;Trametinib:PMID: 23248257, 22805292, 23248257;Vemurafenib:NCCN;Vemurafenib:PMID: 26287849||Dasatinib:PMID: 22649091||Dasatinib:PMID: 22649091||Selumetinib:PMID: 26324360;Sorafenib:PMID: 238900088, 20526349, 24727320;Trametinib:PMID: 24727320, 24345920, 20526349||Sorafenib:PMID: 18794803||Sorafenib:PMID: 18794803||Trametinib:PMID: 23248257, 22805292, 23248257||Vemurafenib:NCCN;Vemurafenib:PMID: 26287849||Vemurafenib:NCCN;Vemurafenib:PMID: 26287849||Vemurafenib:NCCN;Vemurafenib:PMID: 26287849	Cetuximab:PMID: 20619739, 21163703, 23325582;EGFR TK inhibitors:PMID: 22773810;Imatinib:PMID: 25182956;Panitumumab:PMID: 20619739, 21163703, 23325582;Sorafenib:.;Sunitinib:PMID: 25182956||EGFR TK inhibitors:PMID: 22773810;Sorafenib:.||Panitumumab:PMID: 27325282;Vemurafenib:PMID: 27325282||Selumetinib:PMID: 23444215;Vemurafenib:PMID: 23288408, 231718||Selumetinib:PMID: 23444215;Vemurafenib:PMID: 23288408, 231718||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Vemurafenib:PMID: 26732095||Vemurafenib:PMID: 26287849
BRAF	mut	3.00%	RAS/RAF kinase	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	BRAF inhibitors:PMID: 23715574;Trametinib:PMID: 23248257, 22805292, 23248257||BRAF inhibitors:PMID: 22608338;BRAF inhibitors:PMID: 22038996, 22586120;BRAF inhibitor + CDK2/4 inhibitors:PMID: 22997239;BRAF inhibitor + HSP90 inhibitors:PMID: 22351686;BRAF inhibitor + MEK inhibitors:ASCO 2013 (abstr 9029);BRAF inhibitor + PI3K pathway inhibitors:PMID: 22389471, 21156289;Cobimetinib:FDA;Dabrafenib:PMID: 23470635, 22608338;Dabrafenib:PMID: 23470635, 22608338;Dabrafenib:PMID: 23524406, 22608338,ASCO 2013 (abstr 8009),ESMO 2014 (abstr LBA38_PR), 20818844, 23489023, 27080216;Dabrafenib:FDA;Dabrafenib:NCCN;Dabrafenib + Trametinib:PMID: 27048246;Dabrafenib + Trametinib:PMID: 26392102,ASCO 2015 (abstr 8006);Dabrafenib + Trametinib:PMID: 27283860;Dabrafenib + Trametinib:FDA;ERK inhibitors:PMID: 23614898, 22997239;Ipilimumab:PMID: 22382362, 23709751;MEK inhibitors:PMID: 22241789;MEK inhibitors:PMID: 19018267;Panitumumab + Dabrafenib + Trametinib:ASCO 2014 (abstr 3515),ASCO 2015 (abstr 103);Pan-RAF inhibitors:ESMO 2015 (abstract 300),AACR 2016 (abstr CT005);PLX4720:PMC3638050;Selumetinib:NCT01089101;Trametinib:FDA;Vandetanib:PMID: 20065189, 22025146;Vemurafenib:PMID: 22743296, 22621641, 23612012;Vemurafenib:PMID: 22586120;Vemurafenib:PMID: 22608338, 20818844, 23489023;Vemurafenib:FDA;Vemurafenib:PMID: 26287849;Vemurafenib + Cobimetinib:FDA||BYL719:ENA 2014 (abstr 11LBA);Cetuximab:PMID: 27729313;Dabrafenib:ENA 2014 (abstr 11LBA);Irinotecan:PMID: 27729313;Panitumumab:ENA 2014 (abstr 11LBA);Vemurafenib:PMID: 27729313||Cobimetinib:FDA;Dabrafenib + Trametinib:FDA;Ipilimumab:PMID: 22382362, 23709751;Trametinib:FDA;Vemurafenib:NCCN;Vemurafenib:PMID: 26287849;Vemurafenib + Cobimetinib:FDA||Crizotinib:PMID: 27325282;Vemurafenib:PMID: 27325282||Dabrafenib:PMID: 23237741;Ipilimumab:PMID: 22382362, 23709751;Trametinib:PMID: 23248257, 22805292, 23248257;Vemurafenib:NCCN;Vemurafenib:PMID: 26287849||Dasatinib:PMID: 22649091||Dasatinib:PMID: 22649091||Selumetinib:PMID: 26324360;Sorafenib:PMID: 238900088, 20526349, 24727320;Trametinib:PMID: 24727320, 24345920, 20526349||Sorafenib:PMID: 18794803||Sorafenib:PMID: 18794803||Trametinib:PMID: 23248257, 22805292, 23248257||Vemurafenib:NCCN;Vemurafenib:PMID: 26287849||Vemurafenib:NCCN;Vemurafenib:PMID: 26287849||Vemurafenib:NCCN;Vemurafenib:PMID: 26287849	Cetuximab:PMID: 20619739, 21163703, 23325582;EGFR TK inhibitors:PMID: 22773810;Imatinib:PMID: 25182956;Panitumumab:PMID: 20619739, 21163703, 23325582;Sorafenib:.;Sunitinib:PMID: 25182956||EGFR TK inhibitors:PMID: 22773810;Sorafenib:.||Panitumumab:PMID: 27325282;Vemurafenib:PMID: 27325282||Selumetinib:PMID: 23444215;Vemurafenib:PMID: 23288408, 231718||Selumetinib:PMID: 23444215;Vemurafenib:PMID: 23288408, 231718||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Vemurafenib:PMID: 26732095||Vemurafenib:PMID: 26287849
BRAF	mut	3.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	BRAF inhibitors:PMID: 23715574;Trametinib:PMID: 23248257, 22805292, 23248257||BRAF inhibitors:PMID: 22608338;BRAF inhibitors:PMID: 22038996, 22586120;BRAF inhibitor + CDK2/4 inhibitors:PMID: 22997239;BRAF inhibitor + HSP90 inhibitors:PMID: 22351686;BRAF inhibitor + MEK inhibitors:ASCO 2013 (abstr 9029);BRAF inhibitor + PI3K pathway inhibitors:PMID: 22389471, 21156289;Cobimetinib:FDA;Dabrafenib:PMID: 23470635, 22608338;Dabrafenib:PMID: 23470635, 22608338;Dabrafenib:PMID: 23524406, 22608338,ASCO 2013 (abstr 8009),ESMO 2014 (abstr LBA38_PR), 20818844, 23489023, 27080216;Dabrafenib:FDA;Dabrafenib:NCCN;Dabrafenib + Trametinib:PMID: 27048246;Dabrafenib + Trametinib:PMID: 26392102,ASCO 2015 (abstr 8006);Dabrafenib + Trametinib:PMID: 27283860;Dabrafenib + Trametinib:FDA;ERK inhibitors:PMID: 23614898, 22997239;Ipilimumab:PMID: 22382362, 23709751;MEK inhibitors:PMID: 22241789;MEK inhibitors:PMID: 19018267;Panitumumab + Dabrafenib + Trametinib:ASCO 2014 (abstr 3515),ASCO 2015 (abstr 103);Pan-RAF inhibitors:ESMO 2015 (abstract 300),AACR 2016 (abstr CT005);PLX4720:PMC3638050;Selumetinib:NCT01089101;Trametinib:FDA;Vandetanib:PMID: 20065189, 22025146;Vemurafenib:PMID: 22743296, 22621641, 23612012;Vemurafenib:PMID: 22586120;Vemurafenib:PMID: 22608338, 20818844, 23489023;Vemurafenib:FDA;Vemurafenib:PMID: 26287849;Vemurafenib + Cobimetinib:FDA||BYL719:ENA 2014 (abstr 11LBA);Cetuximab:PMID: 27729313;Dabrafenib:ENA 2014 (abstr 11LBA);Irinotecan:PMID: 27729313;Panitumumab:ENA 2014 (abstr 11LBA);Vemurafenib:PMID: 27729313||Cobimetinib:FDA;Dabrafenib + Trametinib:FDA;Ipilimumab:PMID: 22382362, 23709751;Trametinib:FDA;Vemurafenib:NCCN;Vemurafenib:PMID: 26287849;Vemurafenib + Cobimetinib:FDA||Crizotinib:PMID: 27325282;Vemurafenib:PMID: 27325282||Dabrafenib:PMID: 23237741;Ipilimumab:PMID: 22382362, 23709751;Trametinib:PMID: 23248257, 22805292, 23248257;Vemurafenib:NCCN;Vemurafenib:PMID: 26287849||Dasatinib:PMID: 22649091||Dasatinib:PMID: 22649091||Selumetinib:PMID: 26324360;Sorafenib:PMID: 238900088, 20526349, 24727320;Trametinib:PMID: 24727320, 24345920, 20526349||Sorafenib:PMID: 18794803||Sorafenib:PMID: 18794803||Trametinib:PMID: 23248257, 22805292, 23248257||Vemurafenib:NCCN;Vemurafenib:PMID: 26287849||Vemurafenib:NCCN;Vemurafenib:PMID: 26287849||Vemurafenib:NCCN;Vemurafenib:PMID: 26287849	Cetuximab:PMID: 20619739, 21163703, 23325582;EGFR TK inhibitors:PMID: 22773810;Imatinib:PMID: 25182956;Panitumumab:PMID: 20619739, 21163703, 23325582;Sorafenib:.;Sunitinib:PMID: 25182956||EGFR TK inhibitors:PMID: 22773810;Sorafenib:.||Panitumumab:PMID: 27325282;Vemurafenib:PMID: 27325282||Selumetinib:PMID: 23444215;Vemurafenib:PMID: 23288408, 231718||Selumetinib:PMID: 23444215;Vemurafenib:PMID: 23288408, 231718||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Sorafenib:.||Vemurafenib:PMID: 26732095||Vemurafenib:PMID: 26287849
FGFR	mut	9.50%		28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
FGFR	fusion	5.30%		28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
FGFR	fusion	16.00%		25608663	research	11.8	2015	31	ICCA	None	None
HNF1A	mut	5.00%	hepatic differentiation	27262756	Review	7.43	2016	12		None	None
HNF1A		3.00%		.	.	.	.	.	来源于cosmic	None	None
HNF1A	mut	4.70%	hepatic differentiation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
IDH1	mut	13.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	AG-120:NCT02073994, 23558169;Dasatinib:NCT02428855;Venetoclax:PMID: 27520294||Dasatinib:PMID: 27231123	None
IDH1	mut	13.80%		24185509	research	24.17	2013	164	32 iCC，9 gall-bladder carcinomas	AG-120:NCT02073994, 23558169;Dasatinib:NCT02428855;Venetoclax:PMID: 27520294||Dasatinib:PMID: 27231123	None
IDH1		5.90%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	AG-120:NCT02073994, 23558169;Dasatinib:NCT02428855;Venetoclax:PMID: 27520294||Dasatinib:PMID: 27231123	None
IDH2	mut	5.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	AG-221:AACR 2014 (abstr CT103)||AG-221:AACR 2014 (abstr CT103)||Dasatinib:NCT02428855;Venetoclax:PMID: 27520294||Dasatinib:PMID: 27231123	None
IDH2	mut	6.90%		24185509	research	24.17	2013	164	32 iCC，9 gall-bladder carcinomas	AG-221:AACR 2014 (abstr CT103)||AG-221:AACR 2014 (abstr CT103)||Dasatinib:NCT02428855;Venetoclax:PMID: 27520294||Dasatinib:PMID: 27231123	None
IDH2		2.90%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	AG-221:AACR 2014 (abstr CT103)||AG-221:AACR 2014 (abstr CT103)||Dasatinib:NCT02428855;Venetoclax:PMID: 27520294||Dasatinib:PMID: 27231123	None
IL6ST	mut	3.00%	JAK/STAT signalling	27262756	Review	7.43	2016	12		None	None
IL6ST	mut	3.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
IL6ST	mut	1.70%	PI3K/AKT/MTOR pathway,IL6/JAK/STAT pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
KIT	(STV)CNV	2.3%(6/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	Dasatinib:PMID: 16397263||Dasatinib:PMID: 18986703;Dasatinib:PMID: 18559612;Dasatinib:PMID: 16397263||Dasatinib:PMID: 16397263||Dasatinib:PMID: 17372901, 18448188;Imatinib:PMID: 18066592;Imatinib:PMID: 17372901, 18448188;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812;Sunitinib:PMID: 17372901, 18448188||Dasatinib:PMID: 23149070;Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18623623;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 23456621;Imatinib:PMID: 25886408;Imatinib:PMID: 26316776;Sunitinib:PMID: 21394667;Sunitinib:PMID: 21394667||Dasatinib:PMID: 19671763;Imatinib:NCCN;Imatinib:PMID: 18421059, 21642685, 21690468, 22261812;Imatinib:FDA;Nilotinib:PMID: 22068222, 25695690;Regorafenib:FDA;Sunitinib:PMID: 18421059, 21642685, 21690468, 22261812;Sunitinib:FDA||Dasatinib:PMID: 16397263;Sorafenib:ASCO 2011 (abstr 10009);Sunitinib:PMID: 18955458||Imatinib:PMID: 18955458||Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 23456621;Imatinib:PMID: 26779618;Ponatinib:PMID: 25239608||Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18452195;Imatinib:PMID: 18955458||Imatinib:PMID: 15685537||Imatinib:PMID: 18955458||Imatinib:PMID: 16551858;Imatinib:PMID: 18452195||Imatinib:PMID: 15685537||Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 20032375||Imatinib:PMID: 16954519;Imatinib:PMID: 18955458||Imatinib:PMID: 15685537;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 18452195;Imatinib:PMID: 25886408;Sorafenib:PMID: 19461405||Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 18452195;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 25886408||Imatinib:PMID: 23775962;Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 18452195;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 23456621;Imatinib:PMID: 25886408;Nilotinib:PMID: 25695690||Imatinib:PMID: 21325067;Nilotinib:PMID: 21325067;Sorafenib:PMID: 21325067;Sunitinib:PMID: 21325067||Imatinib:PMID: 20043176;Imatinib:PMID: 20043176;Imatinib:PMID: 25886408;Imatinib:PMID: 18066592;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812||Imatinib:PMID: 25886408||Imatinib:PMID: 25886408||Imatinib:PMID: 16954519;Imatinib:PMID: 18623623;Imatinib:PMID: 25886408||Imatinib:PMID: 16551858||Imatinib:PMID: 25735500||Imatinib:PMID: 16551858;Imatinib:PMID: 25886408||Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 20028860;Imatinib:PMID: 25886408;Ponatinib:PMID: 25239608||Imatinib:PMID: 18066592;Imatinib:PMID: 20736294;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812||Imatinib:PMID: 18066592;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812||Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18488000;Imatinib:PMID: 18623623;Imatinib:PMID: 18830121;Imatinib:PMID: 18955458;Imatinib:PMID: 23348204;Imatinib:PMID: 23456621;Imatinib:PMID: 25182956;Imatinib:PMID: 25886408;Imatinib:PMID: 26779618;Ponatinib:PMID: 25239608||Imatinib:PMID: 18066592;Imatinib:PMID: 12960119;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Nilotinib:PMID: 12960119;Sorafenib:PMID: 12960119;Sunitinib:PMID: 22261812;Sunitinib:PMID: 12960119||Imatinib:PMID: 21969494;Imatinib:PMID: 21969494;Nilotinib:PMID: 21969494;Sorafenib:PMID: 21969494;Sunitinib:PMID: 23375402;Sunitinib:PMID: 21969494||Imatinib:PMID: 25886408||Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 20043176;Imatinib:PMID: 23456621;Imatinib:PMID: 25886408||Imatinib:PMID: 15618474||Imatinib:PMID: 15201427||Imatinib:PMID: 25886408||Imatinib:PMID: 15201427;Sunitinib:PMID: 15201427||Imatinib:PMID: 15201427;Sunitinib:PMID: 15201427||Imatinib:PMID: 25886408||Nilotinib:PMID: 22119758, 21456006;Sorafenib:PMID: 23840364||Ponatinib:ASCO 2015 (abstr 10517), 25239608,ASCO 2015 (abstr 10535)||Sorafenib:PMID: 18936790||Sorafenib:PMID: 20970876||Sorafenib:PMID: 18936790, 20372153||Sorafenib:PMID: 22270258||Sunitinib:PMID: 19861435;Sunitinib:PMID: 19861435	Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:PMID: 18955458||Imatinib:.;Sunitinib:.||Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:.;Sunitinib:.||Imatinib:PMID: 24687822||Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:.;Sunitinib:.||Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:PMID: 23582185, 21689725, 17259998;Sunitinib:PMID: 24205792||Imatinib:PMID: 18955458, 18955451, 16624552||Imatinib:FDA||Imatinib:PMID: 23775962;Sunitinib:PMID: 22261812||Imatinib:PMID: 23840364;Sunitinib:PMID: 23840364||Imatinib:PMID: 21690468, 21642685||Imatinib:PMID: 18955458||Sunitinib:PMID: 18955458
KIT	mut	0.90%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Dasatinib:PMID: 16397263||Dasatinib:PMID: 18986703;Dasatinib:PMID: 18559612;Dasatinib:PMID: 16397263||Dasatinib:PMID: 16397263||Dasatinib:PMID: 17372901, 18448188;Imatinib:PMID: 18066592;Imatinib:PMID: 17372901, 18448188;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812;Sunitinib:PMID: 17372901, 18448188||Dasatinib:PMID: 23149070;Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18623623;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 23456621;Imatinib:PMID: 25886408;Imatinib:PMID: 26316776;Sunitinib:PMID: 21394667;Sunitinib:PMID: 21394667||Dasatinib:PMID: 19671763;Imatinib:NCCN;Imatinib:PMID: 18421059, 21642685, 21690468, 22261812;Imatinib:FDA;Nilotinib:PMID: 22068222, 25695690;Regorafenib:FDA;Sunitinib:PMID: 18421059, 21642685, 21690468, 22261812;Sunitinib:FDA||Dasatinib:PMID: 16397263;Sorafenib:ASCO 2011 (abstr 10009);Sunitinib:PMID: 18955458||Imatinib:PMID: 18955458||Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 23456621;Imatinib:PMID: 26779618;Ponatinib:PMID: 25239608||Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18452195;Imatinib:PMID: 18955458||Imatinib:PMID: 15685537||Imatinib:PMID: 18955458||Imatinib:PMID: 16551858;Imatinib:PMID: 18452195||Imatinib:PMID: 15685537||Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 20032375||Imatinib:PMID: 16954519;Imatinib:PMID: 18955458||Imatinib:PMID: 15685537;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 18452195;Imatinib:PMID: 25886408;Sorafenib:PMID: 19461405||Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 18452195;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 25886408||Imatinib:PMID: 23775962;Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 18452195;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 23456621;Imatinib:PMID: 25886408;Nilotinib:PMID: 25695690||Imatinib:PMID: 21325067;Nilotinib:PMID: 21325067;Sorafenib:PMID: 21325067;Sunitinib:PMID: 21325067||Imatinib:PMID: 20043176;Imatinib:PMID: 20043176;Imatinib:PMID: 25886408;Imatinib:PMID: 18066592;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812||Imatinib:PMID: 25886408||Imatinib:PMID: 25886408||Imatinib:PMID: 16954519;Imatinib:PMID: 18623623;Imatinib:PMID: 25886408||Imatinib:PMID: 16551858||Imatinib:PMID: 25735500||Imatinib:PMID: 16551858;Imatinib:PMID: 25886408||Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 20028860;Imatinib:PMID: 25886408;Ponatinib:PMID: 25239608||Imatinib:PMID: 18066592;Imatinib:PMID: 20736294;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812||Imatinib:PMID: 18066592;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812||Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18488000;Imatinib:PMID: 18623623;Imatinib:PMID: 18830121;Imatinib:PMID: 18955458;Imatinib:PMID: 23348204;Imatinib:PMID: 23456621;Imatinib:PMID: 25182956;Imatinib:PMID: 25886408;Imatinib:PMID: 26779618;Ponatinib:PMID: 25239608||Imatinib:PMID: 18066592;Imatinib:PMID: 12960119;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Nilotinib:PMID: 12960119;Sorafenib:PMID: 12960119;Sunitinib:PMID: 22261812;Sunitinib:PMID: 12960119||Imatinib:PMID: 21969494;Imatinib:PMID: 21969494;Nilotinib:PMID: 21969494;Sorafenib:PMID: 21969494;Sunitinib:PMID: 23375402;Sunitinib:PMID: 21969494||Imatinib:PMID: 25886408||Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 20043176;Imatinib:PMID: 23456621;Imatinib:PMID: 25886408||Imatinib:PMID: 15618474||Imatinib:PMID: 15201427||Imatinib:PMID: 25886408||Imatinib:PMID: 15201427;Sunitinib:PMID: 15201427||Imatinib:PMID: 15201427;Sunitinib:PMID: 15201427||Imatinib:PMID: 25886408||Nilotinib:PMID: 22119758, 21456006;Sorafenib:PMID: 23840364||Ponatinib:ASCO 2015 (abstr 10517), 25239608,ASCO 2015 (abstr 10535)||Sorafenib:PMID: 18936790||Sorafenib:PMID: 20970876||Sorafenib:PMID: 18936790, 20372153||Sorafenib:PMID: 22270258||Sunitinib:PMID: 19861435;Sunitinib:PMID: 19861435	Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:PMID: 18955458||Imatinib:.;Sunitinib:.||Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:.;Sunitinib:.||Imatinib:PMID: 24687822||Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:.;Sunitinib:.||Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:PMID: 23582185, 21689725, 17259998;Sunitinib:PMID: 24205792||Imatinib:PMID: 18955458, 18955451, 16624552||Imatinib:FDA||Imatinib:PMID: 23775962;Sunitinib:PMID: 22261812||Imatinib:PMID: 23840364;Sunitinib:PMID: 23840364||Imatinib:PMID: 21690468, 21642685||Imatinib:PMID: 18955458||Sunitinib:PMID: 18955458
KIT	mut	1.30%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Dasatinib:PMID: 16397263||Dasatinib:PMID: 18986703;Dasatinib:PMID: 18559612;Dasatinib:PMID: 16397263||Dasatinib:PMID: 16397263||Dasatinib:PMID: 17372901, 18448188;Imatinib:PMID: 18066592;Imatinib:PMID: 17372901, 18448188;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812;Sunitinib:PMID: 17372901, 18448188||Dasatinib:PMID: 23149070;Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18623623;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 23456621;Imatinib:PMID: 25886408;Imatinib:PMID: 26316776;Sunitinib:PMID: 21394667;Sunitinib:PMID: 21394667||Dasatinib:PMID: 19671763;Imatinib:NCCN;Imatinib:PMID: 18421059, 21642685, 21690468, 22261812;Imatinib:FDA;Nilotinib:PMID: 22068222, 25695690;Regorafenib:FDA;Sunitinib:PMID: 18421059, 21642685, 21690468, 22261812;Sunitinib:FDA||Dasatinib:PMID: 16397263;Sorafenib:ASCO 2011 (abstr 10009);Sunitinib:PMID: 18955458||Imatinib:PMID: 18955458||Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 23456621;Imatinib:PMID: 26779618;Ponatinib:PMID: 25239608||Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18452195;Imatinib:PMID: 18955458||Imatinib:PMID: 15685537||Imatinib:PMID: 18955458||Imatinib:PMID: 16551858;Imatinib:PMID: 18452195||Imatinib:PMID: 15685537||Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 20032375||Imatinib:PMID: 16954519;Imatinib:PMID: 18955458||Imatinib:PMID: 15685537;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 18452195;Imatinib:PMID: 25886408;Sorafenib:PMID: 19461405||Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 18452195;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 25886408||Imatinib:PMID: 23775962;Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 18452195;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 23456621;Imatinib:PMID: 25886408;Nilotinib:PMID: 25695690||Imatinib:PMID: 21325067;Nilotinib:PMID: 21325067;Sorafenib:PMID: 21325067;Sunitinib:PMID: 21325067||Imatinib:PMID: 20043176;Imatinib:PMID: 20043176;Imatinib:PMID: 25886408;Imatinib:PMID: 18066592;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812||Imatinib:PMID: 25886408||Imatinib:PMID: 25886408||Imatinib:PMID: 16954519;Imatinib:PMID: 18623623;Imatinib:PMID: 25886408||Imatinib:PMID: 16551858||Imatinib:PMID: 25735500||Imatinib:PMID: 16551858;Imatinib:PMID: 25886408||Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 20028860;Imatinib:PMID: 25886408;Ponatinib:PMID: 25239608||Imatinib:PMID: 18066592;Imatinib:PMID: 20736294;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812||Imatinib:PMID: 18066592;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Sorafenib:PMID: 18936790;Sunitinib:PMID: 22261812||Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18488000;Imatinib:PMID: 18623623;Imatinib:PMID: 18830121;Imatinib:PMID: 18955458;Imatinib:PMID: 23348204;Imatinib:PMID: 23456621;Imatinib:PMID: 25182956;Imatinib:PMID: 25886408;Imatinib:PMID: 26779618;Ponatinib:PMID: 25239608||Imatinib:PMID: 18066592;Imatinib:PMID: 12960119;Nilotinib:http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032;Nilotinib:PMID: 12960119;Sorafenib:PMID: 12960119;Sunitinib:PMID: 22261812;Sunitinib:PMID: 12960119||Imatinib:PMID: 21969494;Imatinib:PMID: 21969494;Nilotinib:PMID: 21969494;Sorafenib:PMID: 21969494;Sunitinib:PMID: 23375402;Sunitinib:PMID: 21969494||Imatinib:PMID: 25886408||Imatinib:PMID: 15930355;Imatinib:PMID: 16551858;Imatinib:PMID: 16954519;Imatinib:PMID: 17875769;Imatinib:PMID: 18623623;Imatinib:PMID: 18955458;Imatinib:PMID: 20043176;Imatinib:PMID: 23456621;Imatinib:PMID: 25886408||Imatinib:PMID: 15618474||Imatinib:PMID: 15201427||Imatinib:PMID: 25886408||Imatinib:PMID: 15201427;Sunitinib:PMID: 15201427||Imatinib:PMID: 15201427;Sunitinib:PMID: 15201427||Imatinib:PMID: 25886408||Nilotinib:PMID: 22119758, 21456006;Sorafenib:PMID: 23840364||Ponatinib:ASCO 2015 (abstr 10517), 25239608,ASCO 2015 (abstr 10535)||Sorafenib:PMID: 18936790||Sorafenib:PMID: 20970876||Sorafenib:PMID: 18936790, 20372153||Sorafenib:PMID: 22270258||Sunitinib:PMID: 19861435;Sunitinib:PMID: 19861435	Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:PMID: 18955458||Imatinib:.;Sunitinib:.||Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:.;Sunitinib:.||Imatinib:PMID: 24687822||Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:.;Sunitinib:.||Imatinib:PMID: 23582185, 21689725, 17259998||Imatinib:PMID: 23582185, 21689725, 17259998;Sunitinib:PMID: 24205792||Imatinib:PMID: 18955458, 18955451, 16624552||Imatinib:FDA||Imatinib:PMID: 23775962;Sunitinib:PMID: 22261812||Imatinib:PMID: 23840364;Sunitinib:PMID: 23840364||Imatinib:PMID: 21690468, 21642685||Imatinib:PMID: 18955458||Sunitinib:PMID: 18955458
KMT2C	mut	2.00%	Chromatin remodelling	27262756	Review	7.43	2016	12		None	None
KMT2C		4.00%		.	.	.	.	.	来源于cosmic	None	None
KMT2C	mut	3%（28/928）	Chromatin remodeling	26099984	Review	4.91	2015	86		None	None
MLL	mut	22.2%（6/27）；		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	Belinostat:NCT00351975,NCT00357032, 22015773;Daunorubicin:PMID: 22417203;EPZ-5676:NCT02141828,NCT01684150, 21741596	None
MLL	mut	1.7%(2/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	Belinostat:NCT00351975,NCT00357032, 22015773;Daunorubicin:PMID: 22417203;EPZ-5676:NCT02141828,NCT01684150, 21741596	None
MLL	mut	3-4%	Epigenetic modifiers	26099527	Review	7.67	2015	77		Belinostat:NCT00351975,NCT00357032, 22015773;Daunorubicin:PMID: 22417203;EPZ-5676:NCT02141828,NCT01684150, 21741596	None
MLL2	mut	6.00%	transcription	27838634	Review	5.03	2017	8		Bicalutamide:PMID: 27397505	None
MLL2	mut	5.50%	Epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	Bicalutamide:PMID: 27397505	None
MLL2	mut	2-3%	Epigenetic modifiers	26099527	Review	7.67	2015	77		Bicalutamide:PMID: 27397505	None
MLL4	HBV int.	10.00%	Chromatin remodelling	27262756	Review	7.43	2016	12		None	None
MLL4	mut	2.60%	Epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
MLL4	mut	2-3%	Epigenetic modifiers	26099527	Review	7.67	2015	77		None	None
MYC	amp	5.23%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	Temozolomide:PMID: 27397505	None
MYC	amp	1.30%	MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Temozolomide:PMID: 27397505	None
MYC	amp	4.00%	P53-cell cycle pathway	26099527	Review	7.67	2015	77		Temozolomide:PMID: 27397505	None
UBR3	mut	0.8%(1/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
UBR3	mut	2.00%	DNA damage checkpoint and repair	27838634	Review	5.03	2017	8		None	None
UBR3	mut	0.8%(1/120)		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
WWP1	mut	9.00%	SMAD signaling	27838634	Review	5.03	2017	8		None	None
WWP1	mut	7.7%（5/65）		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
WWP1	mut	7.7%(5/65)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
ZIC3		3.00%	Wnt signaling	27838634	Review	5.03	2017	8		None	None
ZIC3	mut	3.3%(4/120)		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
ZIC3	mut	3.3% (4/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
ZNRF3	mut	3.00%	WNT Signalling	27262756	Review	7.43	2016	12		None	None
ZNRF3	mut	3.00%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
ZNRF3		2.90%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	None	None
ARAF	mut	11.00%		25608663	research	11.8	2015	31	ICCA	Sorafenib:http: //www.jci.org/articles/view/72763, 24569458	None
ARAF	mut	5.00%		28297679		8.4	2017	8	仅在第一阶段出现	Sorafenib:http: //www.jci.org/articles/view/72763, 24569458	None
AXIN2	mut	1.00%	WNT Signalling	27262756	Review	7.43	2016	12		None	None
AXIN2	mut	0.90%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
BRCA2	mut	3.70%	genomic instability	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Cisplatin:PMID: 26801247;Olaparib:PMID: 20609467;Olaparib:PMID: 26510020,NCT01682772,http: //cancerres.aacrjournals.org/content/75/15_Supplement/CT322;Olaparib:FDA;Rucaparib:FDA;Veliparib:PMID: 26801247||Niraparib:.||Olaparib:PMID: 22392482	None
BRCA2	mut	3.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	Cisplatin:PMID: 26801247;Olaparib:PMID: 20609467;Olaparib:PMID: 26510020,NCT01682772,http: //cancerres.aacrjournals.org/content/75/15_Supplement/CT322;Olaparib:FDA;Rucaparib:FDA;Veliparib:PMID: 26801247||Niraparib:.||Olaparib:PMID: 22392482	None
CCNE1	HBV int.	5.00%	cell cycle control	27262756	Review	7.43	2016	12		None	None
CCNE1	amp	1.30%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
CDK4	amp	0.40%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	LEE011:NCT02187783,NCT01237236, http: //meetinglibrary.asco.org/content/83791-102||LEE011:NCT02187783,NCT01237236, http: //meetinglibrary.asco.org/content/83791-102	Palbociclib:ASCO 2017 (abstr 9056)
CDK4	amp	5.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	LEE011:NCT02187783,NCT01237236, http: //meetinglibrary.asco.org/content/83791-102||LEE011:NCT02187783,NCT01237236, http: //meetinglibrary.asco.org/content/83791-102	Palbociclib:ASCO 2017 (abstr 9056)
CDKN2B	homo del	5.10%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
CDKN2B	del，mut	3.00%	p53-Rb pathway	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
CREBBP		3.00%		.	.	.	.	.	来源于cosmic	None	None
CREBBP	mut	2.60%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
DAPK1	mut	3.00%	PI3K/MTOR signalling	27262756	Review	7.43	2016	12		None	None
DAPK1	mut	2.60%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
EPHA4	mut	3.00%	RAS/MAPK signalling	27262756	Review	7.43	2016	12		None	None
EPHA4	mut	3.40%	MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
ERRFI1	del	13.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
ERRFI1	mut	3.1%(2/65)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
ERRFI1/MIG6	mut	5.00%	EGFR signaling	27838634	Review	5.03	2017	8		None	None
ERRFI1/MIG6	mut	3.1%（2/65）		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
FGF3	amp	4.00%	RAS/MAPK signalling	27262756	Review	7.43	2016	12		Dovitinib:PMID: 23658459;Lucitanib:PMID: 25193991	None
FGF3	amp	4.30%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Dovitinib:PMID: 23658459;Lucitanib:PMID: 25193991	None
FGFR1	mut	1.70%		28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Lucitanib:PMID: 25193991	Lucitanib:PMID: 25686244
FGFR1	mut	0.90%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Lucitanib:PMID: 25193991	Lucitanib:PMID: 25686244
GXYLT1	mut	0.8%(1/120)		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
GXYLT1	mut	0.8% (1/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
HGF	mut	3.00%	RAS/MAPK signalling	27262756	Review	7.43	2016	12		Cabozantinib:PMID: 25534569	Trastuzumab:PMID: 22850551
HGF	mut	3.00%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Cabozantinib:PMID: 25534569	Trastuzumab:PMID: 22850551
IDH1		15.00%		26405193	research	8.39	2015	19		AG-120:NCT02073994, 23558169;Dasatinib:NCT02428855;Venetoclax:PMID: 27520294||Dasatinib:PMID: 27231123	None
IDH2	mut	11.70%	Epigenetic modifiers	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	AG-221:AACR 2014 (abstr CT103)||AG-221:AACR 2014 (abstr CT103)||Dasatinib:NCT02428855;Venetoclax:PMID: 27520294||Dasatinib:PMID: 27231123	None
IGF2R		18.00%		27838634	Review	5.03	2017	8		None	None
IGF2R	mut	10/928 (1.1)	IGF signalling	26099984	Review	4.91	2015	86		None	None
IGSF10	mut	3.3%(4/120)		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
IGSF10	mut	3.3%(4/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
IGF1R	amp	9.60%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	Erlotinib:PMID: 24458568
IGF1R	mut	1.70%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	Erlotinib:PMID: 24458568
IRF2	mut	4.00%	immune system-inflammation related	27838634	Review	5.03	2017	8		None	None
IRF2	mut,homo del	0.90%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
JAK3	amp	3.00%	JAK/STAT signalling	27262756	Review	7.43	2016	12		JAK inhibitors:PMID: 22705984||JAK inhibitors:PMID: 22705984||JAK inhibitors:PMID: 18397343||JAK inhibitors:PMID: 18397343||JAK inhibitors:PMID: 18397343	None
JAK3	mut，amp	3.00%	PI3K/AKT/MTOR pathway,IL6/JAK/STAT pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	JAK inhibitors:PMID: 22705984||JAK inhibitors:PMID: 22705984||JAK inhibitors:PMID: 18397343||JAK inhibitors:PMID: 18397343||JAK inhibitors:PMID: 18397343	None
KDR	mut	0.40%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	VEGFR inhibitors:PMID: 24569783	None
KDR	mut	5.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	VEGFR inhibitors:PMID: 24569783	None
KMT2D	mut	6.00%	Chromatin remodelling	27262756	Review	7.43	2016	12		None	None
KMT2D		3.00%		.	.	.	.	.	来源于cosmic	None	None
KMT2B	mut	3.00%	Chromatin remodelling	27262756	Review	7.43	2016	12		None	None
KMT2B	mut	12/928 (1.3)	Chromatin remodeling	26099984	Review	4.91	2015	86		None	None
MDM2	amp	1.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	Cisplatin:PMID: 27646943
MDM2	mut,amp	1.70%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	Cisplatin:PMID: 27646943
MTOR	mut	2.00%	PI3K/MTOR signalling	27262756	Review	7.43	2016	12		MTOR kinase inhibitors:PMID: 25295501||Sirolimus:PMID: 24631838||Sirolimus:PMID: 24631838||Sirolimus:PMID: 24631838	None
MTOR	mut	1.70%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	MTOR kinase inhibitors:PMID: 25295501||Sirolimus:PMID: 24631838||Sirolimus:PMID: 24631838||Sirolimus:PMID: 24631838	None
NCOR1	del	22.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
NCOR1	mut	2.00%	chromatin remodeling，β-catenin	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
NRAS	mut	1.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	ERK inhibitors:PMID: 23614898||MEK inhibitor:PMID: 25294897;Sorafenib:PMID: 25294897||Selumetinib:PMID: 22194965	Cetuximab:PMID: 24024839, 20619739, 23325582;Cetuximab:FDA;Panitumumab:PMID: 24024839, 20619739, 23325582;Vemurafenib:PMID: 20179705||Dabrafenib:PMID: 25452114||Dabrafenib:PMID: 24265153;Vemurafenib:PMID: 22194965
NRAS	mut	2.40%	RAS/RAF kinase	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	ERK inhibitors:PMID: 23614898||MEK inhibitor:PMID: 25294897;Sorafenib:PMID: 25294897||Selumetinib:PMID: 22194965	Cetuximab:PMID: 24024839, 20619739, 23325582;Cetuximab:FDA;Panitumumab:PMID: 24024839, 20619739, 23325582;Vemurafenib:PMID: 20179705||Dabrafenib:PMID: 25452114||Dabrafenib:PMID: 24265153;Vemurafenib:PMID: 22194965
PDGFRA	mut	1.70%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Crenolanib:ASCO 2016 (abstr 11010);Dasatinib:PMID: 18794084;HSP90 inhibitors:PMID: 18794084;Imatinib:PMID: 12949711;Imatinib:PMID: 14645423;Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16954519;Imatinib:PMID: 18955458;Imatinib:PMID: 20043176;Imatinib:PMID: 20568982;Imatinib:PMID: 22718859;Imatinib:PMID: 26130666;Sunitinib:PMID: 25735500||Crenolanib:PMID: 24132921;Imatinib:PMID: 24132921||Crenolanib:PMID: 24132921;Imatinib:PMID: 24132921||Crenolanib:PMID: 24132921;Imatinib:PMID: 24132921||Crenolanib:PMID: 24132921;Imatinib:PMID: 24132921||Crenolanib:PMID: 24132921||Dasatinib:PMID: 16397263;Sorafenib:ASCO 2011 (abstr 10009);Sunitinib:PMID: 18955458||Imatinib:NCCN guidelines||Imatinib:NCCN guidelines||Imatinib:NCCN guidelines;Regorafenib:NCCN guidelines;Sunitinib:NCCN guidelines||Imatinib:EMA||Imatinib:EMA||Sunitinib:PMID: 24086736	Imatinib:PMID: 22718859, 16638875;Sunitinib:PMID: 22718859, 16638875||Imatinib:PMID: 12660384||Imatinib:PMID: 14645423, 18955458
PDGFRA	mut	9/928 (1)	PDGFR signalling	26099984	Review	4.91	2015	86		Crenolanib:ASCO 2016 (abstr 11010);Dasatinib:PMID: 18794084;HSP90 inhibitors:PMID: 18794084;Imatinib:PMID: 12949711;Imatinib:PMID: 14645423;Imatinib:PMID: 15685537;Imatinib:PMID: 15930355;Imatinib:PMID: 16954519;Imatinib:PMID: 18955458;Imatinib:PMID: 20043176;Imatinib:PMID: 20568982;Imatinib:PMID: 22718859;Imatinib:PMID: 26130666;Sunitinib:PMID: 25735500||Crenolanib:PMID: 24132921;Imatinib:PMID: 24132921||Crenolanib:PMID: 24132921;Imatinib:PMID: 24132921||Crenolanib:PMID: 24132921;Imatinib:PMID: 24132921||Crenolanib:PMID: 24132921;Imatinib:PMID: 24132921||Crenolanib:PMID: 24132921||Dasatinib:PMID: 16397263;Sorafenib:ASCO 2011 (abstr 10009);Sunitinib:PMID: 18955458||Imatinib:NCCN guidelines||Imatinib:NCCN guidelines||Imatinib:NCCN guidelines;Regorafenib:NCCN guidelines;Sunitinib:NCCN guidelines||Imatinib:EMA||Imatinib:EMA||Sunitinib:PMID: 24086736	Imatinib:PMID: 22718859, 16638875;Sunitinib:PMID: 22718859, 16638875||Imatinib:PMID: 12660384||Imatinib:PMID: 14645423, 18955458
SMC3	mut	3.00%	epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
SMC3	mut	3.00%	Epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
ZNF226	mut	3.3%（4/120）		22634756	research	24.17	2012	438	前者频率来源于27 WGS测序样本，后者来源于验证样本，	None	None
ZNF226	mut	3.3%(4/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
A2M	mut	2.60%	hepatic differentiation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
ABL1	mut	0.40%	MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Axitinib:PMID: 25686603;Dasatinib:PMID: 21931113;Dasatinib:PMID: 26308885;Dasatinib:PMID: 21357704;Dasatinib:PMID: 22873741;Dasatinib:PMID: 21264552;Imatinib:PMID: 11853795;Imatinib:PMID: 21239056;Imatinib:PMID: 25281405;Imatinib:PMID: 11964322;Imatinib:PMID: 12204532;Imatinib:PMID: 12399961;Imatinib:PMID: 12623848;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 19768693;Imatinib:PMID: 19925053;Imatinib:PMID: 20055659;Imatinib:PMID: 20367437;Imatinib:PMID: 20512393;Imatinib:PMID: 20697894;Imatinib:PMID: 21156844;Imatinib:PMID: 21239056;Imatinib:PMID: 21357704;Imatinib:PMID: 21663510;Imatinib:PMID: 22489663;Imatinib:PMID: 22873741;Imatinib:PMID: 23053188;Imatinib:PMID: 23355941;Imatinib:PMID: 23433665;Imatinib:PMID: 23676790;Imatinib:PMID: 24456693;Imatinib:PMID: 11964322;Imatinib:PMID: 12204532;Imatinib:PMID: 14745431;Imatinib:PMID: 21156844;Imatinib:PMID: 23433665;Imatinib:PMID: 23676790;Nilotinib:PMID: 22489663;Ponatinib:FDA;Ponatinib:PMID: 21562040;Ponatinib:PMID: 23190221;Ponatinib:PMID: 23190221;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 22870928;Tyrosine kinase inhibitor - NS:PMID: 21961412;Tyrosine kinase inhibitor - NS:PMID: 21895409;Tyrosine kinase inhibitor - NS:PMID: 20673586;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:PMID: 21562040;Dasatinib:PMID: 21562040;Dasatinib:PMID: 21931113;Dasatinib:PMID: 21156844;Imatinib:PMID: 11853795;Imatinib:PMID: 11964322;Imatinib:PMID: 21239056;Imatinib:PMID: 25281405;Imatinib:PMID: 11964322;Imatinib:PMID: 12204532;Imatinib:PMID: 12399961;Imatinib:PMID: 12623848;Imatinib:PMID: 14745431;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 19768693;Imatinib:PMID: 19925053;Imatinib:PMID: 20512393;Imatinib:PMID: 20697894;Imatinib:PMID: 21239056;Imatinib:PMID: 21357704;Imatinib:PMID: 21663510;Imatinib:PMID: 22873741;Imatinib:PMID: 23053188;Imatinib:PMID: 23355941;Imatinib:PMID: 23676790;Imatinib:PMID: 23799845;Imatinib:PMID: 24456693;Imatinib:PMID: 25807654;Imatinib:PMID: 11853795;Imatinib:PMID: 12204532;Imatinib:PMID: 14745431;Imatinib:PMID: 21156844;Imatinib:PMID: 21221851;Imatinib:PMID: 23676790;Nilotinib:PMID: 21156844;Tyrosine kinase inhibitor - NS:PMID: 20673586;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:PMID: 21562040;Dasatinib:PMID: 21562040;Imatinib:PMID: 11853795;Imatinib:PMID: 25281405;Imatinib:PMID: 12399961;Imatinib:PMID: 12623848;Imatinib:PMID: 19567878;Imatinib:PMID: 19768693;Imatinib:PMID: 21239056;Imatinib:PMID: 21357704;Imatinib:PMID: 21663510;Imatinib:PMID: 23053188;Imatinib:PMID: 23676790;Imatinib:PMID: 14745431;Imatinib:PMID: 21221851;Nilotinib:PMID: 21156844;Tyrosine kinase inhibitor - NS:PMID: 21961412;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:PMID: 21562040;Nilotinib:PMID: 21562040;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:PMID: 21562040;Nilotinib:PMID: 21562040;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:PMID: 21562040;Dasatinib:PMID: 19156415;Dasatinib:PMID: 21357704;Dasatinib:PMID: 22873741;Dasatinib:PMID: 21156844;Dasatinib:PMID: 21264552;Imatinib:PMID: 25281405;Imatinib:PMID: 11964322;Imatinib:PMID: 12204532;Imatinib:PMID: 12623848;Imatinib:PMID: 19567878;Imatinib:PMID: 19768693;Imatinib:PMID: 19925053;Imatinib:PMID: 20367437;Imatinib:PMID: 20512393;Imatinib:PMID: 20697894;Imatinib:PMID: 21156844;Imatinib:PMID: 21221851;Imatinib:PMID: 21357704;Imatinib:PMID: 23053188;Imatinib:PMID: 23433665;Imatinib:PMID: 23676790;Imatinib:PMID: 23799845;Imatinib:PMID: 12204532;Imatinib:PMID: 14745431;Imatinib:PMID: 21264552;Imatinib:PMID: 23433665;Nilotinib:PMID: 21562040;Ponatinib:PMID: 23190221;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 22870928;Tyrosine kinase inhibitor - NS:PMID: 21961412;Tyrosine kinase inhibitor - NS:PMID: 21895409;Tyrosine kinase inhibitor - NS:PMID: 19260121;Tyrosine kinase inhibitor - NS:PMID: 20673586;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:PMID: 21562040;Imatinib:PMID: 20367437;Nilotinib:PMID: 21562040;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:PMID: 21562040;Dasatinib:PMID: 21562040;Imatinib:PMID: 25281405;Imatinib:PMID: 19567878;Imatinib:PMID: 19768693;Imatinib:PMID: 20697894;Imatinib:PMID: 21663510;Imatinib:PMID: 22873741;Imatinib:PMID: 23676790;Imatinib:PMID: 24456693;Nilotinib:PMID: 21156844;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:PMID: 21562040;Bosutinib:PMID: 23044928;Dasatinib:PMID: 21562040;Imatinib:PMID: 19625707;Imatinib:PMID: 21663510;Imatinib:PMID: 23044928;Imatinib:PMID: 23053188;Imatinib:PMID: 21221851;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 21961412;Tyrosine kinase inhibitor - NS:PMID: 19260121||Bosutinib:PMID: 21562040;Bosutinib:PMID: 21357704;Dasatinib:PMID: 21562040;Dasatinib:PMID: 26308885;Imatinib:PMID: 14745431;Imatinib:PMID: 25281405;Imatinib:PMID: 12204532;Imatinib:PMID: 12623848;Imatinib:PMID: 14745431;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 19768693;Imatinib:PMID: 20055659;Imatinib:PMID: 20367437;Imatinib:PMID: 20697894;Imatinib:PMID: 21221851;Imatinib:PMID: 21239056;Imatinib:PMID: 21357704;Imatinib:PMID: 21663510;Imatinib:PMID: 23053188;Imatinib:PMID: 23433665;Imatinib:PMID: 23676790;Imatinib:PMID: 23799845;Imatinib:PMID: 12204532;Imatinib:PMID: 23676790;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 21895409;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:PMID: 23044928||Bosutinib:PMID: 21357704;Imatinib:PMID: 11964322;Imatinib:PMID: 12204532;Imatinib:PMID: 12399961;Imatinib:PMID: 12623848;Imatinib:PMID: 14745431;Imatinib:PMID: 15381060;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 19768693;Imatinib:PMID: 20697894;Imatinib:PMID: 21221851;Imatinib:PMID: 21357704;Imatinib:PMID: 21663510;Imatinib:PMID: 22873741;Imatinib:PMID: 23053188;Imatinib:PMID: 23355941;Imatinib:PMID: 23433665;Imatinib:PMID: 23676790;Imatinib:PMID: 23799845;Imatinib:PMID: 24456693;Imatinib:PMID: 12204532;Imatinib:PMID: 21221851;Nilotinib:PMID: 19156415;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:PMID: 21562040;Dasatinib:PMID: 23044928;Nilotinib:PMID: 21562040;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:PMID: 23086624;Cabozantinib:PMID: 26924578;Crizotinib:PMID: 26924578;Dasatinib:PMID: 26308885;Dasatinib:PMID: 23086624;Foretinib:PMID: 26924578;Imatinib:PMID: 23053188;Imatinib:PMID: 23086624;Nilotinib:PMID: 21562040;Tyrosine kinase inhibitor - NS:PMID: 22870928;Tyrosine kinase inhibitor - NS:PMID: 21961412;Tyrosine kinase inhibitor - NS:PMID: 19260121;Tyrosine kinase inhibitor - NS:PMID: 20673586;Tyrosine kinase inhibitor - NS:PMID: 23223358;Vandetanib:PMID: 26924578||Bosutinib:PMID: 21562040;Dasatinib:PMID: 21562040;Dasatinib:PMID: 21357704;Dasatinib:PMID: 21264552;Imatinib:PMID: 11853795;Imatinib:PMID: 11964322;Imatinib:PMID: 14745431;Imatinib:PMID: 21239056;Imatinib:PMID: 25281405;Imatinib:PMID: 12399961;Imatinib:PMID: 14745431;Imatinib:PMID: 15381060;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 19768693;Imatinib:PMID: 19925053;Imatinib:PMID: 20055659;Imatinib:PMID: 20367437;Imatinib:PMID: 20512393;Imatinib:PMID: 20697894;Imatinib:PMID: 21156844;Imatinib:PMID: 21221851;Imatinib:PMID: 21239056;Imatinib:PMID: 21357704;Imatinib:PMID: 22873741;Imatinib:PMID: 23053188;Imatinib:PMID: 23355941;Imatinib:PMID: 23433665;Imatinib:PMID: 23676790;Imatinib:PMID: 23799845;Imatinib:PMID: 24456693;Imatinib:PMID: 26413254;Imatinib:PMID: 12204532;Imatinib:PMID: 14745431;Imatinib:PMID: 21156844;Imatinib:PMID: 21221851;Imatinib:PMID: 21264552;Nilotinib:PMID: 22873741;Tyrosine kinase inhibitor - NS:PMID: 21895409;Tyrosine kinase inhibitor - NS:PMID: 20673586;Tyrosine kinase inhibitor - NS:PMID: 23223358||Bosutinib:FDA;Dasatinib:PMID: 27582059;Dasatinib:FDA;Imatinib:EMA;Nilotinib:FDA;Ponatinib:FDA||Dasatinib:PMID: 23044928||Dasatinib:PMID: 21264552;Imatinib:PMID: 21239056;Imatinib:PMID: 12623848;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 19768693;Imatinib:PMID: 19925053;Imatinib:PMID: 20055659;Imatinib:PMID: 20367437;Imatinib:PMID: 20512393;Imatinib:PMID: 20682399;Imatinib:PMID: 20697894;Imatinib:PMID: 21221851;Imatinib:PMID: 21357704;Imatinib:PMID: 21663510;Imatinib:PMID: 22873741;Imatinib:PMID: 23053188;Imatinib:PMID: 23433665;Imatinib:PMID: 23676790;Imatinib:PMID: 23799845;Imatinib:PMID: 24456693;Imatinib:PMID: 25807654;Imatinib:PMID: 26413254;Imatinib:PMID: 11964322;Imatinib:PMID: 12204532;Imatinib:PMID: 21156844;Imatinib:PMID: 21221851;Imatinib:PMID: 21264552;Imatinib:PMID: 23676790;Nilotinib:PMID: 21357704;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 22870928;Tyrosine kinase inhibitor - NS:PMID: 21961412;Tyrosine kinase inhibitor - NS:PMID: 21895409;Tyrosine kinase inhibitor - NS:PMID: 19260121;Tyrosine kinase inhibitor - NS:PMID: 20673586;Tyrosine kinase inhibitor - NS:PMID: 23223358||Imatinib:PMID: 23053188;Tyrosine kinase inhibitor - NS:PMID: 20673586||Imatinib:PMID: 20697894;Imatinib:PMID: 21221851;Imatinib:PMID: 24456693||Imatinib:PMID: 23053188;Tyrosine kinase inhibitor - NS:PMID: 21961412||Imatinib:PMID: 19567878;Imatinib:PMID: 21156844||Imatinib:PMID: 23433665||Imatinib:PMID: 14745431;Imatinib:PMID: 19567878;Imatinib:PMID: 19925053;Imatinib:PMID: 20697894;Imatinib:PMID: 24456693;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 21895409||Imatinib:PMID: 23676790||Imatinib:PMID: 19625707||Imatinib:PMID: 23799845||Imatinib:PMID: 23676790||Imatinib:PMID: 22873741;Ponatinib:PMID: 23190221||Imatinib:PMID: 20697894||Imatinib:PMID: 19625707||Imatinib:PMID: 19625707||Imatinib:PMID: 19567878;Imatinib:PMID: 19625707||Imatinib:PMID: 19625707||Imatinib:PMID: 19625707||Imatinib:PMID: 20697894||Imatinib:PMID: 19567878;Imatinib:PMID: 24456693||Imatinib:PMID: 25281405;Imatinib:PMID: 12399961;Imatinib:PMID: 12623848;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 19925053;Imatinib:PMID: 20055659;Imatinib:PMID: 20697894;Imatinib:PMID: 21221851;Imatinib:PMID: 21663510;Imatinib:PMID: 22873741;Imatinib:PMID: 23053188;Imatinib:PMID: 23676790;Imatinib:PMID: 23799845;Imatinib:PMID: 24456693;Imatinib:PMID: 25740611;Imatinib:PMID: 12204532;Tyrosine kinase inhibitor - NS:PMID: 19260121;Tyrosine kinase inhibitor - NS:PMID: 20673586;Tyrosine kinase inhibitor - NS:PMID: 23223358||Imatinib:PMID: 20697894||Imatinib:PMID: 20512393;Imatinib:PMID: 20697894||Imatinib:PMID: 19625707;Imatinib:PMID: 20512393;Imatinib:PMID: 23053188||Imatinib:PMID: 19768693||Imatinib:PMID: 23676790||Imatinib:PMID: 19625707||Imatinib:PMID: 23799845||Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Ponatinib:PMID: 23190221||Imatinib:PMID: 20697894||Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 23676790||Imatinib:PMID: 12623848;Imatinib:PMID: 19567878;Imatinib:PMID: 19768693;Imatinib:PMID: 20512393;Imatinib:PMID: 20697894;Imatinib:PMID: 21156844;Imatinib:PMID: 21239056;Imatinib:PMID: 21357704;Imatinib:PMID: 22873741;Imatinib:PMID: 23799845;Imatinib:PMID: 20697894;Imatinib:PMID: 21156844;Tyrosine kinase inhibitor - NS:PMID: 23223358||Imatinib:PMID: 19567878||Imatinib:PMID: 23053188||Imatinib:PMID: 19567878;Imatinib:PMID: 19925053;Imatinib:PMID: 21239056;Imatinib:PMID: 21663510;Imatinib:PMID: 21264552||Imatinib:PMID: 21221851;Imatinib:PMID: 23433665;Tyrosine kinase inhibitor - NS:PMID: 21961412;Tyrosine kinase inhibitor - NS:PMID: 23223358||Imatinib:PMID: 20697894;Imatinib:PMID: 20697894||Imatinib:PMID: 14745431||Imatinib:PMID: 19625707;Imatinib:PMID: 12204532||Imatinib:PMID: 12623848;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 21221851;Imatinib:PMID: 21239056;Imatinib:PMID: 22873741;Imatinib:PMID: 23053188||Imatinib:PMID: 19625707||Imatinib:PMID: 24456693||Imatinib:PMID: 25740611||Imatinib:PMID: 11853795;Imatinib:PMID: 22299775;Imatinib:PMID: 25281405;Imatinib:PMID: 19625707||Imatinib:PMID: 12204532;Imatinib:PMID: 12399961;Imatinib:PMID: 12623848;Imatinib:PMID: 14745431;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 19768693;Imatinib:PMID: 19925053;Imatinib:PMID: 20055659;Imatinib:PMID: 20697894;Imatinib:PMID: 21221851;Imatinib:PMID: 22873741;Imatinib:PMID: 23053188;Imatinib:PMID: 23676790;Imatinib:PMID: 24456693;Imatinib:PMID: 12204532;Nilotinib:PMID: 22873741;Ponatinib:PMID: 23190221;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 21961412;Tyrosine kinase inhibitor - NS:PMID: 23223358||Imatinib:PMID: 19625707;Imatinib:PMID: 20697894||Imatinib:PMID: 21264552||Imatinib:PMID: 23053188||Imatinib:PMID: 22873741||Imatinib:PMID: 12623848;Imatinib:PMID: 17008892;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 19925053;Imatinib:PMID: 20055659;Imatinib:PMID: 20367437;Imatinib:PMID: 20697894;Imatinib:PMID: 21221851;Imatinib:PMID: 21663510;Tyrosine kinase inhibitor - NS:PMID: 23223358||Imatinib:PMID: 19625707;Imatinib:PMID: 19925053;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 20673586||Imatinib:PMID: 19567878;Imatinib:PMID: 20697894;Imatinib:PMID: 21221851;Imatinib:PMID: 21663510;Tyrosine kinase inhibitor - NS:PMID: 23223358||Imatinib:PMID: 25281405||Imatinib:PMID: 23433665||Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 20367437;Imatinib:PMID: 21221851||Imatinib:PMID: 19925053;Imatinib:PMID: 20697894;Imatinib:PMID: 26413254;Tyrosine kinase inhibitor - NS:PMID: 21961412;Tyrosine kinase inhibitor - NS:PMID: 23223358||Imatinib:PMID: 23676790;Ponatinib:PMID: 23190221||Imatinib:PMID: 12204532;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 20367437;Imatinib:PMID: 22873741;Imatinib:PMID: 23676790;Imatinib:PMID: 24456693;Tyrosine kinase inhibitor - NS:PMID: 21895409;Tyrosine kinase inhibitor - NS:PMID: 23223358||Imatinib:PMID: 22299775;Imatinib:PMID: 25281405;Imatinib:PMID: 12204532;Imatinib:PMID: 12399961;Imatinib:PMID: 12623848;Imatinib:PMID: 19156415;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 19768693;Imatinib:PMID: 19925053;Imatinib:PMID: 20055659;Imatinib:PMID: 20367437;Imatinib:PMID: 20697894;Imatinib:PMID: 21156844;Imatinib:PMID: 21221851;Imatinib:PMID: 21239056;Imatinib:PMID: 21663510;Imatinib:PMID: 22873741;Imatinib:PMID: 23053188;Imatinib:PMID: 23433665;Imatinib:PMID: 23676790;Imatinib:PMID: 21221851;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 21961412;Tyrosine kinase inhibitor - NS:PMID: 21895409;Tyrosine kinase inhibitor - NS:PMID: 23223358||Imatinib:PMID: 12204532||Imatinib:PMID: 23053188||Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Tyrosine kinase inhibitor - NS:PMID: 21895409||Imatinib:PMID: 24456693||Imatinib:PMID: 20055659||Imatinib:PMID: 25281405||Imatinib:PMID: 19768693||Imatinib:PMID: 15381060||Imatinib:PMID: 12399961;Imatinib:PMID: 12623848;Imatinib:PMID: 12623848;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 20367437;Imatinib:PMID: 21221851;Imatinib:PMID: 21239056;Imatinib:PMID: 21663510;Imatinib:PMID: 22489663;Imatinib:PMID: 22873741;Imatinib:PMID: 23799845;Imatinib:PMID: 12204532;Imatinib:PMID: 21156844;Ponatinib:PMID: 23190221;Tyrosine kinase inhibitor - NS:PMID: 21961412;Tyrosine kinase inhibitor - NS:PMID: 23223358||Imatinib:PMID: 21156844||Imatinib:PMID: 25281405||Imatinib:PMID: 12204532||Imatinib:PMID: 19625707||Imatinib:PMID: 12623848;Imatinib:PMID: 19625707;Imatinib:PMID: 19768693;Imatinib:PMID: 23433665||Imatinib:PMID: 23053188;Imatinib:PMID: 23676790||Imatinib:PMID: 23053188;Imatinib:PMID: 23433665||Imatinib:PMID: 14745431||Imatinib:PMID: 23053188||Imatinib:PMID: 21663510;Imatinib:PMID: 23355941;Imatinib:PMID: 24456693||Imatinib:PMID: 12204532;Imatinib:PMID: 19625707;Imatinib:PMID: 23433665;Imatinib:PMID: 26413254;Tyrosine kinase inhibitor - NS:PMID: 20673586||Imatinib:PMID: 25281405;Imatinib:PMID: 12399961;Imatinib:PMID: 12623848;Imatinib:PMID: 19567878;Imatinib:PMID: 19625707;Imatinib:PMID: 19925053;Imatinib:PMID: 20055659;Imatinib:PMID: 20367437;Imatinib:PMID: 21239056;Imatinib:PMID: 23799845;Imatinib:PMID: 12204532;Tyrosine kinase inhibitor - NS:PMID: 20673586||Imatinib:PMID: 23053188||Imatinib:PMID: 21663510;Tyrosine kinase inhibitor - NS:PMID: 20673586||Imatinib:PMID: 25186176;Trametinib:PMID: 25186176||Nilotinib:PMID: 23044928||Ponatinib:PMID: 23190221||Tyrosine kinase inhibitor - NS:PMID: 23223358||Tyrosine kinase inhibitor - NS:PMID: 20673586||Tyrosine kinase inhibitor - NS:PMID: 21961412||Tyrosine kinase inhibitor - NS:PMID: 21961412||Tyrosine kinase inhibitor - NS:PMID: 19260121||Tyrosine kinase inhibitor - NS:PMID: 23223358||Tyrosine kinase inhibitor - NS:PMID: 21961412||Tyrosine kinase inhibitor - NS:PMID: 23223358	Bosutinib:.;Dasatinib:.;Imatinib:.;Nilotinib:.||Bosutinib:.;Dasatinib:.;Imatinib:.;Nilotinib:.||Bosutinib:.;Dasatinib:.;Imatinib:.;Nilotinib:.||Bosutinib:.;Dasatinib:.;Imatinib:.;Nilotinib:.||Bosutinib:PMID: 21562040;Dasatinib:PMID: 21562040;Imatinib:PMID: 21562040;Nilotinib:PMID: 21562040||Bosutinib:.;Dasatinib:.;Imatinib:.;Nilotinib:.||Dasatinib:PMID: 20673586||Dasatinib:PMID: 19260121, PMID: 20673586;Imatinib:PMID: 21562040||Dasatinib:PMID: 21562040;Imatinib:PMID: 21562040||Dasatinib:PMID: 21562040;Imatinib:PMID: 21562040||Dasatinib:PMID: 21562040;Imatinib:PMID: 21562040||Dasatinib:PMID: 21562040;Imatinib:PMID: 21562040||Dasatinib:PMID: 19260121;Imatinib:PMID: 21562040;Nilotinib:PMID: 21562040||Dasatinib:PMID: 20673586;Imatinib:PMID: 21562040||Dasatinib:PMID: 21562040;Imatinib:PMID: 23223358||Dasatinib:PMID: 19260121||Dasatinib:PMID: 21562040;Imatinib:PMID: 21562040||Dasatinib:PMID: 20673586;Imatinib:PMID: 21562040||Dasatinib:PMID: 20673586;Imatinib:PMID: 21562040||Dasatinib:PMID: 20673586||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040;Nilotinib:PMID: 21562040||Imatinib:PMID: 21562040;Nilotinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 20697894||Imatinib:PMID: 21562040;Nilotinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040;Nilotinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21264552||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040;Nilotinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040||Imatinib:PMID: 21562040
ACTL6A	mut	0.90%	chromatin remodeling	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
ACTL6B	mut	0.40%	chromatin remodeling	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
ADH1B	mut	1.80%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
AHCTF1	mut	4.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
ARIS1A	mut	7.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
ASH1L	SNP、Indel、SV	4.3%(13/300)	chromatin regulators	27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
ASXL1	mut	2.80%	other	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
ATK	mut	0.90%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
ATR	mut	2.10%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	Olaparib:PMID: 23548269||Olaparib:PMID: 23548269;Temozolomide:PMID: 23960094	None
AXL	mut	1.70%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
AZIN1	mut	3.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
BPTF	mut	1.7%(2/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
BRD7	mut	2.00%	chromatin remodeling	25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
BRD8	mut	6.9%(2/29)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
CBL	(STV)CNV	2.3%(7/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	Dasatinib:PMID: 23696637;JAK inhibitors:PMID: 23696637||Dasatinib:PMID: 23696637;JAK inhibitors:PMID: 23696637	None
CDH2		2.90%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	None	None
CDKN1B	mut	1.00%	Cell cycle	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
CFH	mut，homo del/amp	2.60%	hepatic differentiation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
CFHR1	mut，homo del/amp	1.70%	hepatic differentiation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
CFHR2	homo del	0.40%	hepatic differentiation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
CHD7	mut	3.40%	Epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
CNND1	amp	5-10%	Ras/raf/mapk,Akt/mtor	26099527	Review	7.67	2015	77		None	None
CPS1	SNP、Indel、SV	5.3%(16/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
CYP2E2	mut	2.00%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
EEF1A1	mut	3.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
ELF	mut	5.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	None	None
ELF3	mut	6.30%	other	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
EP300	mut	2.10%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
EPHA2		2.90%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	Dasatinib:PMID: 20360610;MTOR inhibitors:PMID: 20360610||Dasatinib:PMID: 18047674, 19010823, 19861960	None
ERBB3	amp	1.30%		28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Afatinib:PMID: 27044931;Afatinib:ASCO 2015 (abstr e15516);ERBB3 mAb inhibitors:PMID: 23680147;Lapatinib:PMID: 23680147;Pertuzumab:PMID: 23680147;PI3K pathway inhibitor + MEK inhibitors:PMID: 23680147;Trastuzumab:PMID: 23680147||Afatinib:PMID: 27044931;Afatinib:ASCO 2015 (abstr e15516)||Afatinib:PMID: 27044931||ERBB3 mAb inhibitors:PMID: 23680147;Lapatinib:PMID: 23680147;Pertuzumab:PMID: 23680147;PI3K pathway inhibitor + MEK inhibitors:PMID: 23680147;Trastuzumab:PMID: 23680147||Lapatinib:PMID: 23680147;PI3K pathway inhibitor + MEK inhibitors:PMID: 23680147;Trastuzumab:PMID: 23680147	Bosutinib:.||Bosutinib:.
EYS	SNP、Indel、SV	8%(24/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
F8	mut	2.60%	hepatic differentiation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
FAK	amp	4.00%	Ras/raf/mapk	26099527	Review	7.67	2015	77		None	None
FAM123B	(STV)CNV	2.3%(7/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
FAT4		3.00%		.	.	.	.	.	来源于cosmic	None	None
FBXW7	mut	3.70%	TGF-β	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Sirolimus:PMID: 23558291	None
FCRL1	mut	2.00%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
FGA	mut	3.40%	hepatic differentiation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
FGF	amp	5-10%	Ras/raf/mapk,Akt/mtor	26099527	Review	7.67	2015	77		None	None
FGF4	amp	4.70%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Dovitinib:PMID: 23658459;Lucitanib:PMID: 25193991	None
FGFR4	mut	0.40%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	Everolimus:PMID:  22986737
FGFR3	mut	0.90%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	Bortezomib:PMID: 19331127, 21273588||FGFR inhibitors:PMID: 16091734, 20439987, 22869148	Bortezomib:PMID: 19331127, 21273588||FGFR inhibitors:PMID: 22869148;PD173074:PMID: 22869148
FLT4	mut	3.40%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
FLT1	mut	1.30%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Sunitinib:PMID: 24086736, 21478036;Sunitinib:PMID: 24086736, 21478036	None
FLT3	mut	0.90%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Crenolanib:PMID: 24619500;Midostaurin:PMID: 24619500||Lestaurtinib:PMID: 16857985;Midostaurin:PMID: 20733134||Quizartinib:PMID: 22504184||Quizartinib:PMID: 22504184||Quizartinib:PMID: 22354205;Quizartinib:PMID: 22504184;Sorafenib:PMID: 22368270;Sunitinib:PMID: 23969938||Quizartinib:PMID: 22504184;Quizartinib:PMID: 23392356;Sorafenib:PMID: 23969938||Quizartinib:ASH 2012 (abstr 673),ASH 2012 (abstr 48);Sorafenib:PMID: 19389879, 22368270;Sorafenib:PMID: 23613521||Sorafenib:PMID: 22368270||Sorafenib:PMID: 23969938;Sorafenib:PMID: 22368270;Sorafenib:PMID: 23969938	Ponatinib:PMID: 23430109||Quizartinib:PMID: 22504184, 23878140||Venetoclax:PMID: 27520294
FZXR1	mut	1.70%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
GDF1	amp	0.40%	TGFβ pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
GDF15	amp	0.40%	TGFβ pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
GPATCH4	mut	2.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
GNAS	mut	3.00%		28297679		8.4	2017	8	仅在第一阶段出现	None	None
HIST1H1C	mut	2.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
HUWEI	mut，amp	3.40%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
IL6R	mut	0.90%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
JAK2	amp	11.30%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	JAK inhibitor (alone or in combination)s:PMID: 22829971;Ruxolitinib:PMID: 22422826;Ruxolitinib:FDA||Ruxolitinib:PMID: 22875628, 22899477	NS-018:PMID: 24766055;Ruxolitinib:PMID: 21926964, PMID: 24766055
KMT2A	mut	2.9%（27/928）	Chromatin remodeling	26099984	Review	4.91	2015	86		None	None
LAMA2	mut	5-12%	unclear	27838634	Review	5.03	2017	8		None	None
LRP1B	SNP、Indel、SV	18%(54/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
LRP1B		6.00%		.	.	.	.	.	来源于cosmic	None	None
MACROD2	SV	11.3%(34/300)	DNA-repair genes	27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
LZTR1	mut	3.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
MACF1	mut	2.60%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
MAP2K7	mut	1.30%	MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
MAP3K10	mut	1.30%	MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
MAP2K1	mut	0.90%	MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	ERK inhibitors:PMID: 23614898||ERK inhibitors:PMID: 23614898||ERK inhibitors:PMID: 23614898||novel MEK inhibitors:PMID: 24448821||Panitumumab + Trametinib:PMID: 26644315||Selumetinib:PMID: 26324360||Trametinib:PMID: 26582713	AZD6244:PMID: 19915144, PMID: 21383288, PMID: 23444215;MEK inhibitors:PMID: 19915144, 23444215, 21383288||AZD6244:PMID: 19915144;MEK inhibitors:PMID: 19915144||AZD6244:PMID: 19915144;MEK inhibitors:PMID: 19915144||AZD6244:PMID: 19915144;MEK inhibitors:PMID: 19915144||AZD6244:PMID: 19915144;MEK inhibitors:PMID: 19915144||AZD6244:PMID: 19915144;Dabrafenib:PMID: 25452114;MEK inhibitors:PMID: 19915144||AZD6244:PMID: 19915144;MEK inhibitors:PMID: 19915144||AZD6244:PMID: 19915144;MEK inhibitors:PMID: 19915144||AZD6244:PMID: 19915144;MEK inhibitors:PMID: 19915144||AZD6244:PMID: 19915144;MEK inhibitors:PMID: 19915144||AZD6244:PMID: 19915144;MEK inhibitors:PMID: 19915144||AZD6244:PMID: 19915144, PMID: 21383288, PMID: 23444215;MEK inhibitors:PMID: 19915144, 23444215, 21383288||AZD6244:PMID: 19915144;MEK inhibitors:PMID: 19915144||AZD6244:PMID: 19915144, PMID: 21383288, PMID: 23444215;MEK inhibitors:PMID: 19915144;MEK inhibitors:PMID: 19915144, 23444215, 21383288||AZD6244:PMID: 19915144;BRAF inhibitors:PMID: 19915144, 21383288;Dabrafenib:PMID: 24265153;MEK inhibitors:PMID: 19915144;PLX4720:PMID: 19915144, PMID: 21383288||AZD6244:PMID: 19915144;BRAF inhibitors:PMID: 19915144, 21383288;MEK inhibitors:PMID: 19915144;PLX4720:PMID: 19915144, PMID: 21383288;Vemurafenib:PMID: 23569304||AZD6244:PMID: 19915144;MEK inhibitors:PMID: 19915144||Dabrafenib:PMID: 24463458;Vemurafenib:PMID: 23569304||Vemurafenib:PMID: 23569304
MAP2K4	mut	2.00%	RAS/RAF kinase	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
MAP2K3	del，mut	2.00%		25362482	research	22.76	2014	106	503例样本（488 HCC，15 IHCC）,文献附件无法下载，根据图标预估比例	None	None
MDM4	amp	3.60%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
MLL5	mut	1.30%	Epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
MUC17	mut	4.7%(14/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
MSH3	mut	1.70%	genomic instability	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
NCOR2	mut	2.60%	Epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
NF1	mut	3.00%		28297679		8.4	2017	8	38 CCA（34个是ICC）。进一步用15个样本验证。该部分为两个样本集都有的	Bevacizumab:PMID: 24232489, 2485933;Erlotinib:PMID: 22434731;Everolimus:PMID: 26859683,ASCO 2016 (abstr e17557);Imatinib:PMID: 23099009;Nilotinib:PMID: 24173684;Nilotinib:ASCO 2016 (abstr 10555);PLX3397:PMID: 23099891;Selumetinib:ASCO 2014 (abstr 10018);Sirolimus:PMID: 25314964;Sirolimus:PMID: 22434731;Sirolimus:PMID: 25810463;Sorafenib:PMID: 25810463;Tamoxifen:PMID: 21075781;Trametinib:PMID: 26936308;Trametinib:PMID: 24576830, 2524381;Vinblastine:ASCO 2016 (abstr 2019);Vinblastine:ASCO 2016 (abstr 10555)||Bevacizumab:PMID: 24232489, 2485933;Erlotinib:PMID: 22434731;Everolimus:NCT01365468;Everolimus:PMID: 26859683,ASCO 2016 (abstr e17557);Everolimus:PMID: 24931142;Imatinib:PMID: 23099009;Nilotinib:PMID: 24173684;Nilotinib:ASCO 2016 (abstr 10555);Pazopanib:PMID: 24931142;PLX3397:PMID: 23099891;Selumetinib:ASCO 2014 (abstr 10018);Sirolimus:PMID: 25314964;Sirolimus:PMID: 22434731;Sirolimus:PMID: 25810463;Sorafenib:PMID: 25810463;Tamoxifen:PMID: 21075781;Trametinib:PMID: 26936308;Trametinib:PMID: 24576830, 2524381;Vinblastine:ASCO 2016 (abstr 2019);Vinblastine:ASCO 2016 (abstr 10555)	Bevacizumab:ASCO 2016 (abstr 11053);Cediranib:NCT00326872;Dasatinib:PMID: 24296828;Erlotinib:PMID: 24535670;Erlotinib:PMID: 24634382;Everolimus:NCT01365468;Everolimus:ASCO 2016 (abstr 11053);Everolimus:PMID: 24634382;Tipifarnib:PMID: 24500418;Trametinib:PMID: 26325560||Bevacizumab:ASCO 2016 (abstr 11053);Cediranib:NCT00326872;Dasatinib:PMID: 24296828;Erlotinib:PMID: 24535670;Erlotinib:PMID: 24634382;Everolimus:NCT01365468;Everolimus:ASCO 2016 (abstr 11053);Everolimus:PMID: 24634382;Tipifarnib:PMID: 24500418;Trametinib:PMID: 26325560||dasatinib:PMID: 24296828||Selumetinib:PMID: 23444215;Vemurafenib:PMID: 23288408, 231718||Selumetinib:PMID: 23444215;Vemurafenib:PMID: 23288408, 231718||Vemurafenib:PMID: 23171796
NF2	mut	3.00%		28297679		8.4	2017	8	仅在第一阶段出现	AR42:PMID: 21778190;AR42:ASCO 2016 (abstr 2558);Bevacizumab:PMID: 19587327, 22805104, 26022982;Everolimus:PMID: 24311643,2556735;Everolimus:PMID: 26015296;Imatinib:PMID: 19509233, 2290085;Lapatinib:PMID: 22844108,NCT00973739;Octreotide:PMID: 26015296;Tensirolimus:PMID: 25878190||AR42:PMID: 21778190;AR42:ASCO 2016 (abstr 2558);Bevacizumab:PMID: 19587327, 22805104, 26022982;Everolimus:PMID: 24311643,2556735;Everolimus:PMID: 26015296;Imatinib:PMID: 19509233, 2290085;Lapatinib:PMID: 22844108,NCT00973739;Octreotide:PMID: 26015296;Tensirolimus:PMID: 25878190	Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||Cetuximab:PMID: 24813888;Erlotinib:PMID: 24813888||Erlotinib:PMID: 20736812||Erlotinib:PMID: 20736812
NRAS/KRAS/HRAS:	mut	3.00%	Ras/raf/mapk	26099527	Review	7.67	2015	77		None	None
p16INK4A		6-30%	oxidative stress response	27838634	Review	5.03	2017	8		None	None
ODZ1		4.40%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	None	None
OTOP1	mut	0.8% (1/120)		22634756	research	24.17	2012	443	25 HCC（11 HBV，14 HCV)；120 HCC validation set	None	None
PBRM1	mut,homo del	1.70%	chromatin remodeling	25822088	research	23.17	2015	153	243 样本（14% HBV）	Everolimus:PMID: 25997916	None
PDGFRB	mut	0.90%	MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
PCLO		5.90%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	None	None
PHF20L1	mut	1.70%	Epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
PDGFRB4	mut	0.90%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
PIK3C2B	mut	1.30%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
PIK3CG	mut	1.30%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Everolimus:PMID: 29285035	None
PIK3C2A	mut	0.90%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
PIK3IP1	mut	0.90%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
PIK3C2G	mut	0.40%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
PIK3R1	mut	2.60%	RAS/RAF kinase	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
PIK3R6	mut	1.30%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
PIK3R2	mut	0.90%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	MTOR inhibitors:PMID: 21984976, 19962665||MTOR inhibitors:PMID: 21984976, 19962665	None
PIK3R4	mut	0.90%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
PREX2		3.00%		.	.	.	.	.	来源于cosmic	None	None
PRKDC	mut	2.10%	p53/cell cycle	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
RASA1	mut	4.00%	RAS/RAF kinase	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
RAS‡	mut	12/928 (1.3)	Ras/PI3K/mTOR pathway	26099984	Review	4.91	2015	86		None	None
RP1L1	mut	3.00%		28622513	research	22.79	2017	21	来源于363 HCC WES样本，其中196例收录在TCGA中	None	None
RET	mut	1.30%	MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	Cabozantinib:PMID: 21470995;RET inhibitors:PMID: 23056499;Sunitinib:PMID: 21470995;Vandetanib:PMID: 20065189, 22025146||Cabozantinib:PMID: 21470995;RET inhibitors:PMID: 23056499;Sunitinib:PMID: 21470995;Vandetanib:PMID: 20065189, 22025146;Vandetanib:PMID: 20368568||Cabozantinib:PMID: 28447912;Nintedanib:PMID: 26787234;Sunitinib:PMID: 28447912;Vandetanib:PMID: 28447912||Cabozantinib:PMID: 21470995;Sunitinib:PMID: 21470995;Vandetanib:PMID: 21470995||Vandetanib:PMID: 20065189, 22025146	Vandetanib:PMID: 24336963
RNF43	mut	4.70%	WNT signalling	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
RSK2	mut	2-9%	Akt/mtor	26099527	Review	7.67	2015	77		None	None
SETDB1	mut	4%（12/300）	chromatin regulators	27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
SETD2	mut	2.60%	Epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
SLX4	mut	2.60%	Epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
SMARCA2	mut	2.60%	chromatin remodeling	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
SMARCC2	mut	1.30%	chromatin remodeling	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
SMARCB1	mut	0.90%	chromatin remodeling	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
SMARCA4	mut	0.40%	chromatin remodeling	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
SMARCC1	mut	0.40%	chromatin remodeling	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
SMAD4	mut	13.00%	TGF-β	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
SRCAP	mut	3.00%	Epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
SMCHD1	mut	2.60%	Epigenetic regulation	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
STAT1	mut	0.40%	IL6/JAK/STAT pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
STAT2	mut	0.40%	IL6/JAK/STAT pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
STAT4	mut	0.40%	IL6/JAK/STAT pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
STAT5A	mut	0.40%	IL6/JAK/STAT pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
SOS1	mut	1.79%	MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
TCF7L2	mut	2.10%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
TEK	mut	1.30%	PI3K/AKT/MTOR pathway,MAP kinase pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
STK11	mut	5.00%	RAS/RAF kinase	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	Phenformin:PMID: 23352126||Phenformin:PMID: 23352126	Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996||Docetaxel:PMID: 22425996;MEK inhibitor:PMID: 22425996
TGRBR2	mut	2.50%	RAS/RAF kinase	28667006	research	3.46	2017	5	489 CCA(ICC和ECC）,94例DNA测序	None	None
SYT2		2.90%		25636086	research	11.23	2015	30	30例胆汁表现的肝癌，60 HCC WGS，数据收录在ICGC	None	None
USP34	mut	2.60%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
TTC28	SV为主	8%(24/300)		27064257	research	20.83	2017	54	样本量300(HCC 268,24 ICC,8 Chcc/icc)	None	None
WNT10B	mut	0.90%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
WNT10A	mut	0.40%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
WNT7B	mut	0.40%	WNT/β-catenin pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
PIK3CD	mut	0.40%	PI3K/AKT/MTOR pathway	25822088	research	23.17	2015	153	243 样本（14% HBV）	None	None
